

CURRICULUM VITAE
Anoop M. Nambiar

GENERAL INFORMATION

PERSONAL DATA:

Address: 7703 Floyd Curl Dr.
MC 7885
San Antonio, TX 78229

Phone Number: (210) 617-5256

Fax Number: (210) 949-3006

Email Address: Nambiar@uthscsa.edu

EDUCATION:

<u>Year</u>	<u>Degree</u>	<u>Discipline</u>	<u>Institution/Location</u>
2003	MD	Medicine	University of Medicine & Dentistry of New Jersey-New Jersey Medical School, Newark, NJ
1999	BA	Molecular Biology & Biochemistry (<i>magna cum laude</i>)	Rutgers, The State University of New Jersey, New Brunswick, NJ

TRAINING:

Fellowship

<u>Year</u>	<u>Discipline</u>	<u>Institution/Location</u>
2006- 2009	Pulmonary & Critical Care Medicine	University of Michigan Health System, Ann Arbor, MI

Internship

<u>Year</u>	<u>Discipline</u>	<u>Institution/Location</u>
2003- 2006	Internal Medicine	University of Michigan Health System, Ann Arbor, MI

Master of Science

<u>Year</u>	<u>Discipline</u>	<u>Institution/Location</u>
2011- 2016	Clinical Investigation	University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

Residency

<u>Year</u>	<u>Discipline</u>	<u>Institution/Location</u>
2004-	Internal Medicine	University of Michigan Health System, Ann Arbor,

ACADEMIC APPOINTMENTS:

09/2016 - Present	Associate Professor of Medicine and Director of Interstitial Lung Disease Program	University of Texas Health Science Center at San Antonio, Department of Medicine, San Antonio, TX
09/2010 - 08/2016	Assistant Professor of Medicine and Director of Interstitial Lung Disease Program	University of Texas Health Science Center at San Antonio, Department of Medicine, San Antonio, TX
07/2009 - 06/2010	Clinical Lecturer & Consultant Physician and Clinical Lecturer	University of Otago, Department of General Medicine and Respiratory Medicine, Invercargill, New Zealand

Details: This was a one-year locum tenens position in which I served as the only pulmonologist for the city of Invercargill, NZ and surrounding areas with a population of about 50,000 people. In addition to functioning as a staff physician on the acute inpatient general medicine service, I also solely conducted inpatient pulmonary consultations as well as both inpatient and outpatient flexible bronchoscopies. I performed the first-ever transbronchial needle aspiration procedure at Southland Hospital, a procedure which helped confirm a diagnosis and stage of lung cancer for many patients without the need for an invasive surgery.

07/2007 - 06/2009	Physician	University of Michigan Health System, Department of Department of Internal Medicine, Ann Arbor, MI
-------------------	-----------	--

Details: Physician Moonlighter, Bone Marrow Transplant Unit, Division of Hematology and Oncology.

NON-ACADEMIC APPOINTMENTS:

12/2010 - Present	Staff Physician	South Texas Veterans Healthcare System, San Antonio, TX
-------------------	-----------------	---

Details: Division of Pulmonary Diseases & Critical Care Medicine

11/2010 - Present	Staff Physician	University Hospital, University Health System, San Antonio, TX
-------------------	-----------------	--

Details: Division of Pulmonary Diseases & Critical Care Medicine

CERTIFICATION AND LICENSURE:***Board Certification***

<u>Description/Agency</u>	<u>Status</u>	<u>Date Acquired</u>	<u>Number</u>	<u>Expiration</u>
---------------------------	---------------	----------------------	---------------	-------------------

Board Certification - American Board of Internal Medicine - Critical Care Medicine	Certified	10/2009	n/a	12/2029
Board Certification - Pulmonary Disease - American Board of Internal Medicine - Pulmonary Disease	Certified	11/2008	n/a	12/2028
Board Certification - American Board of Internal Medicine - Internal Medicine	Certified	09/2006	n/a	12/2016

Certification

<u>Description/Agency</u>	<u>Status</u>	<u>Date Acquired</u>	<u>Number</u>	<u>Expiration</u>
Basic Life Support Certification - American Heart Association (BLS)	Certified	12/2010	n/a	10/2020
DPS - Controlled Substances Registration Certificate - Texas Department of Public Safety	Certified	09/2010	J0176212	08/2020
DEA - Controlled Substance Registration Certificate - United States Department of Justice, Drug Enforcement Administration	Certified	10/2008	BN9610204	10/2020
Advanced Cardiovascular Life Support (ACLS) - American Heart Association (ACLS)	Certified	10/2008	n/a	10/2020

License to Practice

<u>Description/Agency</u>	<u>Status</u>	<u>Date Acquired</u>	<u>Number</u>	<u>Expiration</u>
Physician Full Permit - License - Texas Medical Board	Educ Qualified	09/2010	N7644	08/2020
New Zealand Medical License - Medical Council of New Zealand	Certified	07/2009	n/a	06/2010

HONORS AND AWARDS:

- 11/2019 Recognition of Service Award from the PFF: In recognition of my service as co-chairperson for the Pulmonary Fibrosis Foundation (PFF) Summit 2019. I was invited by Dr. Greg Cosgrove, PFF Chief Medical Office, to co-chair the Summit and was intimately involved with creation, design, and coordination of the PFF Summit 2019 held in San Antonio, Texas in November 2019.
- 09/2019 Mayoral Proclamation of Pulmonary Fibrosis Awareness Month, September 2019: As medical director of the SA Pulmonary Fibrosis Support Group and along with the Pulmonary Fibrosis Foundation (PFF), we requested and were granted an official Proclamation by the Mayor of San Antonio, Mr. Ron Nirenberg, of September 2019 as

"Global Pulmonary Fibrosis Awareness Month." Importantly, this proclamation recognized the concerted efforts of our local group and the PFF to raise awareness globally about pulmonary fibrosis, provide educational resources for patients, caregivers, and healthcare providers, and assist with medical research funding to advance scientific endeavors towards better treatments and ultimately a cure.

- 08/2019 2019 Pulmonary Fibrosis Foundation Leanne Storch Support Group Fund Award: For the 5th straight year and 6th time, Dot Delarosa (founder of the San Antonio Pulmonary Fibrosis Support Group) and I were amongst the awardees in 2017. See description for the 2012 award for details about the Fund. We will use this grant to help fund our 3rd Semi-annual Free ILD/IPF Clinic.. The purpose of the free clinic is to allow patients and families who have either suspected or confirmed interstitial lung disease or pulmonary fibrosis to obtain an expert second opinion regarding their diagnosis and management at no cost.
- 09/2018 Award of Appreciation from the SA PF Support Group: Inscription: "Appreciation-- And September being Pulmonary Fibrosis Awareness Month, We Hereby Honor Dr. Anoop Nambiar For Your Passion, Unconditional Commitment, Enduring Dedication, Love, and Compassion. Thank you! We Love You! San Antonio Pulmonary Fibrosis Support Group, September 2018"
- 09/2018 Certificate of Appreciation from the UT Health SA IRB: In recognition of my 5th year anniversary during FY 2018, the "IRB expresses our deepest appreciation and gratitude to you for your dedicated service." In addition to being a voting IRB member, I was also invited to serve as Vice-chair of IRB-1, assisting with leading and coordinating reviews of clinical research protocols at UTHSA and affiliated institutions.
- 09/2018 Mayoral Proclamation of Pulmonary Fibrosis Awareness Month, September 2018: As medical director of the SA Pulmonary Fibrosis Support Group and along with the Pulmonary Fibrosis Foundation (PFF), we requested and were granted an official Proclamation by the Mayor of San Antonio, Mr. Ron Nirenberg, of September 2018 as "Global Pulmonary Fibrosis Awareness Month." Importantly, this proclamation recognized the concerted efforts of our local group and the PFF to raise awareness globally about pulmonary fibrosis, provide educational resources for patients, caregivers, and healthcare providers, and assist with medical research funding to advance scientific endeavors towards better treatments and ultimately a cure.
- 08/2018 2018 Pulmonary Fibrosis Foundation Leanne Storch Support Group Fund Award: For the 4th straight year and 5th time, Dot Delarosa (founder of the San Antonio Pulmonary Fibrosis Support Group) and I were amongst the awardees in 2017. See description for the 2012 award for details about the Fund. We will use this grant to help fund our 3rd Semi-annual Free ILD/IPF Clinic.. The purpose of the free clinic is to allow patients and families who have either suspected or confirmed interstitial lung disease or pulmonary fibrosis to obtain an expert second opinion regarding their diagnosis and management at no cost.
- 11/2017 UT Health IRB Service Award: Perfect attendance for 2017 on UT Health IRB-1
- 09/2017 Mayoral Proclamation of Pulmonary Fibrosis Awareness Month, September 2017: As medical director of the SA Pulmonary Fibrosis Support Group and along with the Pulmonary Fibrosis Foundation (PFF), we requested and were granted an official

Proclamation by the Mayor of San Antonio, Mr. Ron Nirenberg, of September 2017 as "Global Pulmonary Fibrosis Awareness Month." Importantly, this proclamation recognized the concerted efforts of our local group and the PFF to raise awareness globally about pulmonary fibrosis, provide educational resources for patients, caregivers, and healthcare providers, and assist with medical research funding to advance scientific endeavors towards better treatments and ultimately a cure.

- 08/2017 2017 Pulmonary Fibrosis Foundation Leanne Storch Support Group Fund Award: For the 4th straight year and 5th time, Dot Delarosa (founder of the San Antonio Pulmonary Fibrosis Support Group) and I were amongst the awardees in 2017. See description for the 2012 award for details about the Fund. We will use this grant to help fund our 3rd Semi-annual Free ILD/IPF Clinic.. The purpose of the free clinic is to allow patients and families who have either suspected or confirmed interstitial lung disease or pulmonary fibrosis to obtain an expert second opinion regarding their diagnosis and management at no cost.
- 08/2016 2016 Pulmonary Fibrosis Foundation Leanne Storch Support Group Fund Award: For the 3rd straight year and 4th time, Dot Delarosa (founder of the San Antonio Pulmonary Fibrosis Support Group) and I were amongst the awardees in 2015. See description for the 2012 award for details about the Fund. We will use this grant to help fund our 3rd Semi-annual Free ILD/IPF Clinic. The purpose of the free clinic is to allow patients and families who have either suspected or confirmed interstitial lung disease or pulmonary fibrosis to obtain an expert second opinion regarding their diagnosis and management at no cost.
- 05/2016 UTHSCSA Department of Medicine Research Day Faculty Award for Best Poster: Only faculty awarded best poster for my work on "Effectiveness and Safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis." Travel award given.
- 07/2015 2015 Pulmonary Fibrosis Foundation Leanne Storch Support Group Fund Award: For the 2nd straight year and 3rd time, Dot Delarosa (founder of the San Antonio Pulmonary Fibrosis Support Group) and I were amongst the awardees in 2015. See description for the 2012 award for details about the Fund. We will use this grant to help fund our 3rd Semi-annual Free ILD/IPF Clinic in August 2015. The purpose of the free clinic is to allow patients and families who have either suspected or confirmed interstitial lung disease or pulmonary fibrosis to obtain an expert second opinion regarding their diagnosis and management at no cost.
- 08/2014 2014 Pulmonary Fibrosis Foundation Leanne Storch Support Group Fund Award: Dot Delarosa (founder of the San Antonio Pulmonary Fibrosis Support Group) and I were one of only 16 awardees in 2014. See description for the 2012 award for details about the Fund. We used this grant to help fund our very successful 2nd Free ILD/IPF Clinic in February 2015. The purpose of the free clinic is to allow patients and families who have either suspected or confirmed interstitial lung disease or pulmonary fibrosis to obtain an expert second opinion regarding their diagnosis and management at no cost. Those that attended included some patients and families who financially are unable to see a pulmonary specialist, but more often patients and families desired a second opinion that they were unable to get in their community. We also used the funds to help support performing pulmonary function and exercise testing at no cost.

- 12/2012 2012 Pulmonary Fibrosis Foundation Leanne Storch Support Group Fund Award: In the inaugural year for this award, Dot Delarosa (founder of the San Antonio Pulmonary Fibrosis Support Group) and I were one of only six awardees in the United States to receive this honor. The Fund is named for the Foundation's former Executive Director, who was diagnosed with PF in 2003. The Leanne Storch Support Group Fund honors Leanne's enduring passion for supporting those affected by pulmonary fibrosis. The Pulmonary Fibrosis Foundation is dedicated to assisting the all-volunteer pulmonary fibrosis (PF) support group community to engage their local PF patients, caregivers and family members, establish new support groups and host meaningful educational events. The Leanne Storch Support Group Fund enhances the PFF Support Group Leader Network by providing funding to assist the leaders in meeting the objectives of their local groups. We used the 2012 award towards funding a portable video projector which I use to conduct engaging and interactive presentations on various topics regarding interstitial lung diseases and idiopathic pulmonary fibrosis.
- 01/2006 Employee Recognition Program Award: University of Michigan Medical Center, Ann Arbor, MI
- 01/2005 Employee Recognition Program Award: University of Michigan Medical Center, Ann Arbor, MI
- 01/2001 Employee Recognition Program Award: University of Michigan Medical Center, Ann Arbor, MI
- 01/2001 Early Start Mentoring Program Achievement Award
- 01/2000 Employee Recognition Program Award: University of Michigan Medical Center, Ann Arbor, MI
- 01/2000 Alumni Scholarship: University of Medicine & Dentistry of New Jersey-New Jersey Medical School (UMDNJ-NJMS)
- 01/1999 Alumni Scholarship: University of Medicine & Dentistry of New Jersey-New Jersey Medical School (UMDNJ-NJMS)
- 01/1999 Henry Rutgers Scholar: Rutgers University, New Brunswick, NJ
- 01/1998 Research Fellowship Award: Waksman Institute of Microbiology/ Rutgers University, New Brunswick, NJ

PROFESSIONAL DEVELOPMENT:

Clinical

<u>Date</u>	<u>Description</u>	<u>C.E. Units/Hours</u>
11/07/2019 - 11/09/2019	PFF Summit 2019, I attended, presented, and co-chaired the PFF Summit 2019 held in San Antonio, TX.	12.00 / 12.00
10/19/2019 - 10/23/2019	CHEST 2019, I attended and presented at CHEST Annual Meeting 2019 held in New Orleans, LA.	12.00 / 12.00
11/09/2017 - 11/11/2017	PFF Summit 2017, Pulmonary Fibrosis Foundation	10.00 / 10.00

	Summit 2017 held in Nashville, TN. I was chosen to serve on the Rural Outreach Working Group for the PFF Care Center Network.	
10/28/2017 - 11/01/2017	CHEST 2017, CHEST International Conference held in Toronto, Canada. I co-chaired the Interdisciplinary ILD Session and was an invited speaker for Multidisciplinary approach to care, "ILD Centers of Excellence Come of Age."	10.00 / 10.00
11/12/2015 - 11/14/2015	PFF Summit 2015, Pulmonary Fibrosis Foundation held in Washington, D.C.	10.00 / 10.00
05/17/2015 - 05/20/2015	American Thoracic Society (ATS) 2015 International Conference: Denver, CO, Clinical areas of CME: Idiopathic pulmonary fibrosis, interstitial lung diseases, sarcoidosis, bronchoscopy, and interesting case presentations.	14.75 / 14.75
05/16/2014 - 05/21/2014	American Thoracic Society (ATS) 2014 International Conference: San Diego, C, Clinical areas of CME: Interstitial lung diseases, idiopathic pulmonary fibrosis, etc.	17.50 / 17.50
12/05/2013 - 12/07/2013	PFF Summit 2013, Pulmonary Fibrosis Foundation International Summit 2013, Both clinical and research CME areas on various topics on interstitial lung diseases and idiopathic pulmonary fibrosis.	10.75 / 10.75
05/17/2013 - 05/22/2013	American Thoracic Society (ATS) 2013 International Conference, Clinical areas of CME include: interstitial lung diseases, idiopathic pulmonary fibrosis, etc.	19.50 / 19.50
12/11/2012	Release of Updated American College of Physicians Ethics Manual	0.25 / 0.25
05/18/2012 - 05/23/2012	American Thoracic Society (ATS) 2012 International Conference, Clinical areas of CME include: interstitial lung diseases, idiopathic pulmonary fibrosis, etc.	20.00 / 20.00
05/13/2011 - 05/18/2011	American Thoracic Society (ATS) 2011 International Conference, Clinical areas of CME include: interstitial lung diseases, idiopathic pulmonary fibrosis, etc.	12.50 / 12.50
10/18/2010	UTHSCSA - Training, HIPPA Level 3 Training, University of Texas Health Science Center at San Antonio, Texas	0.00 / 0.00
09/23/2010	UTHSCSA - Safety Training, Safety - Bloodborne Pathogens Training, University of Texas Health Science Center at San Antonio, Texas	0.50 / 0.50
11/14/2009 - 11/18/2009	Asian Pacific Society of Respiriology Congress - 2009, Seoul, South Korea	0.00 / 0.00
09/12/2009 - 09/16/2009	European Respiratory Society Congress - 2009, Vienna, Austria	0.00 / 0.00
05/15/2009 - 05/20/2009	American Thoracic Society International Conf - 2009,	0.00 / 0.00

01/04/2009	San Diego, CA ACCP Course - 2009, Ultrasonography in Critical Care, American College of Chest Physicians, Ft. Lauderdale, FL	0.00 / 0.00
05/15/2008 - 05/21/2008	American Thoracic Society International Conf - 2008, Toronto, Canada	0.00 / 0.00
01/02/2008	Midwest Fellows Conference - 2008, Midwest Fellows Conference on Interventional Pulmonology, Ohio State University, Columbus, OH	0.00 / 0.00

Other

<u>Date</u>	<u>Description</u>	<u>C.E. Units/Hours</u>
12/01/2011 - 12/03/2011	Pulmonary Fibrosis Foundation IPF Summit 2011: From Bench to Bedside, Clinical and research CME on various topics on interstitial lung diseases and idiopathic pulmonary fibrosis.	13.00 / 13.00
09/15/2010	UTHSCSA - GCAT, General Compliance Awareness Training, University of Texas Health Science Center at San Antonio, Texas	0.00 / 0.00

Research

<u>Date</u>	<u>Description</u>	<u>C.E. Units/Hours</u>
09/28/2019 - 10/02/2019	ERS 2019, I attended and presented at the European Respiratory Society International Congress 2019 held in Madrid, Spain.	15.00 / 15.00
05/18/2019 - 05/22/2019	ATS 2019, I attended and presented at the American Thoracic Society International Conference 2019 held in Dallas, TX.	15.00 / 15.00
10/06/2018 - 10/10/2018	CHEST 2018, I attended and presented preliminary data for our pilot research study on senolytic therapy in IPF.	0.00 / 0.00
05/20/2018 - 05/23/2018	ATS 2018, American Thoracic Society International Conference in San Diego, CA	15.00 / 15.00
05/19/2017 - 05/24/2017	ATS 2017, American Thoracic Society International Conference held in Washington, D.C. I presented a Meet The Professor Session entitled "Real World Challenges in the Diagnosis of IPF." I was also co-author on a couple of abstracts and posters.	15.00 / 15.00
09/24/2016 - 09/28/2016	ICLAF 2016, International Colloquium on Lung and Airway Fibrosis 2016 held in Dublin, Ireland. I presented a poster "Effectiveness and Safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis."	10.00 / 10.00

05/13/2016 - 05/18/2016	ATS 2016, American Thoracic Society (ATS) 2016 International Conference held in San Francisco, California	17.00 / 17.00
05/17/2015 - 05/20/2015	American Thoracic Society (ATS) 2015 International Conference: Denver, CO, Research areas of CME: "Genomics will revolutionize care of chronic lung disease," "Advancing the foundation for global IPF clinical research"	4.00 / 4.00
05/18/2014 - 05/21/2014	American Thoracic Society (ATS) 2014 International Conference: San Diego, C, CME research areas include: "NEJM/JAMA reports of recently published pulmonary research", "Evolving role of genetics in the care of pulmonary fibrosis," "Scientific breakthroughs of the year: aging and senescence"	7.50 / 7.50
01/10/2014 - 05/15/2014	Integrating Molecular Biology with Patient-Oriented Clinical Research, This interdisciplinary course was designed to train participants on integrating molecular biology methods into patient-oriented clinical research	0.00 / 30.00
01/10/2013 - 05/15/2013	Data Management, Quality Control, and Regulatory Issues, This interdisciplinary course was designed to train participants in the necessary data-management and quality-control procedures required for the conduct of patient-oriented clinical research.	0.00 / 30.00
01/10/2013 - 05/15/2013	Grantsmanship and Peer Review, The purpose of this elective course is to provide an overview of the peer review process for research proposals as well as the essential components of grant management.	0.00 / 30.00
08/20/2012 - 12/20/2012	Responsible Conduct of Patient-Oriented Clinical Research, Interdisciplinary course designed to train participants in the responsible conduct of patient-oriented clinical research	0.00 / 30.00
08/20/2012 - 12/11/2012	Health Services Research, This course focused on concepts and methods used in research, specifically on health care quality, utilization, access, and safety.	0.00 / 30.00
01/10/2012 - 05/30/2012	Patient-Oriented Clinical Research Methods-2, Learned to 1) define criteria for inferring causation from observational studies, 2) design strategies for subject retention in a prospective study, 3) design strategies for monitoring progress in a randomized control trial, 4) delineate strategies for minimizing bias in cohort studies and randomized control trials, 5) compare and contrast the uses, strengths, and weaknesses of different clinical trial designs, 6) read and interpret research reports of cohort studies and randomized control trials, and 7) describe the steps in conducting a meta-analysis.	0.00 / 30.00

01/10/2012 - 05/23/2012	Patient-Oriented Clinical Research Biostatistics-2, Learned to 1) perform a two-way analysis of variance and explain the results, 2) perform survival analysis, 3) compare and contrast the purpose and characteristics of different forms of interventional trials, and 4) plan the sample size, analysis, and stopping rules of a randomized clinical trial.	0.00 / 30.00
08/24/2011 - 12/31/2011	Patient-Oriented Clinical Research Biostatistics-1, Learned to 1) identify and summarize different categories of data, 2) set up and perform tests of hypothesis, 3) estimate sample sizes for survey and case-control studies, and 4) use statistical software packages to enter, summarize, graph, visualize, and analyze data.	0.00 / 30.00
08/24/2011 - 12/31/2011	Patient-Oriented Clinical Research Methods-1, Learned to 1) define a research question, 2) effectively conduct a systematic review of the scientific literature, 3) design strategies for recruitment into a study, 4) delineate strategies for minimizing bias in cross-sectional and retrospective studies, and 5) read and interpret research reports of cross-sectional and case-control investigations	0.00 / 30.00

TEACHING

COURSE BASED TEACHING:

<u>Date</u>	<u>Course Name</u>	<u>Level</u>	<u>Role</u>
02/2020 - 02/2020	MEDI2002 Adv Physical Diagnosis	Post Graduate	Preceptor

Preparation Hrs: 2, Student Contact Hrs: 10 ; I am a faculty preceptor for an annual lab for the MS1 class during which I instruct small groups (5-6) of first-year medical students throughout the afternoon activity on the intricacies of the pulmonary exam using volunteer patients who have pulmonary abnormalities. The focus of the interaction is on the approach to the patient with lung disease with an emphasis on physical examination abnormalities. My function during the lab is to instruct students on how to approach the physical exam, give feedback on physical examination technique and discuss the reasoning for such abnormalities. In the school of medicine's current curriculum, this is the student's first lab interaction with patients that have known physical examination abnormalities. Each afternoon, the total duration of lab is 2.5 hours with 55 students instructed. I typically serve as preceptor for the lab 4 afternoons every year.

02/2020 - 02/2020 MEDI4170 Internal Medicine Post Graduate Lecturer
Internship Readiness Elective

Preparation Hrs: 6, Student Contact Hrs: 2 ; Title of lecture: "Chest CT for Interns" The goal of this course is to prepare fourth year students for the knowledge, behavior, and skills necessary for internship in Internal Medicine, including diagnosis and management of common medicine topics and proficiency in communication, patient evaluation, and procedures. Also briefly discussed radiologic findings in COVID-19 pneumonia.

04/2019 - 04/2019 MEDI4170 Internal Medicine Post Graduate Lecturer
Internship Readiness Elective

Preparation Hrs: 6, Student Contact Hrs: 2 ; Title of lecture: "Chest CT for Interns" The goal of this course is to prepare fourth year students for the knowledge, behavior, and skills necessary for internship in Internal Medicine, including diagnosis and management of common medicine topics and proficiency in communication, patient evaluation, and procedures.

02/2019 - 02/2019 MEDI2002 Adv Physical Post Graduate Preceptor
Diagnosis

Preparation Hrs: 2, Student Contact Hrs: 10 ; I am a faculty preceptor for an annual lab for the MS1 class during which I instruct small groups (5-6) of first-year medical students throughout the afternoon activity on the intricacies of the pulmonary exam using volunteer patients who have pulmonary abnormalities. The focus of the interaction is on the approach to the patient with lung disease with an emphasis on physical examination abnormalities. My function during the lab is to instruct students on how to approach the physical exam, give feedback on physical examination technique and discuss the reasoning for such abnormalities. In the school of medicine's current curriculum, this is the student's first lab interaction with patients that have known physical examination abnormalities. Each afternoon, the total duration of lab is 2.5 hours with 55 students instructed. I typically serve as preceptor for the lab 4 afternoons every year.

02/2019 - 02/2019 MEDI4170 Internal Medicine Post Graduate Lecturer
Internship Readiness Elective

Preparation Hrs: 6, Student Contact Hrs: 2 ; Title of lecture: "Chest CT for Interns" The goal of this course is to prepare fourth year students for the knowledge, behavior, and skills necessary for internship in Internal Medicine, including diagnosis and management of common medicine topics and proficiency in communication, patient evaluation, and procedures.

09/2018 - Present RESC5041 Clinical Practice Post Graduate Preceptor
Introduction

Preparation Hrs: 2, Student Contact Hrs: 125 ; I was invited by Mrs. Kristina Ramirez, Director of Respiratory Care (RC) Clinical Education, to serve as preceptor for her student's clinical rotations. Every week, one 2nd-year Respiratory Care student would visit my afternoon clinic. We would discuss different respiratory diseases, diagnosis, differential diagnoses, pathophysiology, and treatment. They would interact directly with patients along with me. Following the patient encounter, we would de-brief about what they learned. Select comments from students include: "I really enjoyed following Dr. Nambiar and learning about the different types of ILD. It is easy to see that Dr. Nambiar enjoys teaching students because he takes the time to explain different aspects and answer questions I have. Dr. Nambiar is very caring and compassionate with his patients who are living with ILD and would really take the time to answer their questions and concerns. I highly recommend students to follow Dr. Nambiar as part of their clinical rotation so they can learn more in depth about ILD and use that knowledge in their career as a RT," and "Dr. Nambiar did a great job explaining the patients disease processes to both myself and the patient. He is very friendly and seems to be very passionate about his job and helping his patients feel better."

02/2018 - 02/2018 MEDI2002 Adv Physical Post Graduate Preceptor
Diagnosis

Preparation Hrs: 2, Student Contact Hrs: 10 ; I am a faculty preceptor for an annual lab for the MSI class during which I instruct small groups (5-6) of first-year medical students throughout the afternoon activity on the intricacies of the pulmonary exam using volunteer patients who have pulmonary abnormalities. The focus of the interaction is on the approach to the patient with lung disease with an emphasis on physical examination abnormalities. My function during the lab is to instruct students on how to approach the physical exam, give feedback on physical examination technique and discuss the reasoning for such abnormalities. In the school of medicine's current curriculum, this is the student's first lab interaction with patients that have known physical examination abnormalities. Each afternoon, the total duration of lab is 2.5 hours with 55 students instructed. I typically serve as preceptor for the lab 4 afternoons every year.

02/2018 - 02/2018 MEDI4170 Internal Medicine Post Graduate Lecturer
Internship Readiness Elective

Preparation Hrs: 6, Student Contact Hrs: 2 ; Title of lecture: "Chest CT for Interns" The goal of this course is to prepare fourth year students for the knowledge, behavior, and skills necessary for internship in Internal Medicine, including diagnosis and management of common medicine topics and proficiency in communication, patient evaluation, and procedures.

04/2017 - 04/2017 MEDI4170 Internal Medicine Post Graduate Lecturer
Internship Readiness Elective

Preparation Hrs: 6, Student Contact Hrs: 2 ; Title of lecture: "Chest CT for Interns" The goal of this course is to prepare fourth year students for the knowledge, behavior, and skills necessary for internship in Internal Medicine, including diagnosis and management of common medicine topics and proficiency in communication, patient evaluation, and procedures.

02/2017 - 02/2017 MEDI2002 Adv Physical Post Graduate Preceptor
Diagnosis

Preparation Hrs: 2, Student Contact Hrs: 10 ; I am a faculty preceptor for an annual lab for the MS1 class during which I instruct small groups (5-6) of first-year medical students throughout the afternoon activity on the intricacies of the pulmonary exam using volunteer patients who have pulmonary abnormalities. The focus of the interaction is on the approach to the patient with lung disease with an emphasis on physical examination abnormalities. My function during the lab is to instruct students on how to approach the physical exam, give feedback on physical examination technique and discuss the reasoning for such abnormalities. In the school of medicine's current curriculum, this is the student's first lab interaction with patients that have known physical examination abnormalities. Each afternoon, the total duration of lab is 2.5 hours with 55 students instructed. I typically serve as preceptor for the lab 4 afternoons every year.

02/2017 - 02/2017 MEDI4170 Internal Medicine Post Graduate Lecturer
Internship Readiness Elective

Preparation Hrs: 6, Student Contact Hrs: 2 ; Title of lecture: "Chest CT for Interns" The goal of this course is to prepare fourth year students for the knowledge, behavior, and skills necessary for internship in Internal Medicine, including diagnosis and management of common medicine topics and proficiency in communication, patient evaluation, and procedures.

04/2016 - 04/2016 MEDI4170 Internal Medicine Post Graduate Lecturer
Internship Readiness Elective

Preparation Hrs: 5, Student Contact Hrs: 2 ; MS4 Bootcamp Title of lecture: "Chest CT for Interns" The goal of this course is to prepare fourth year students for the knowledge, behavior, and skills necessary for internship in Surgery, including diagnosis and management of common medicine topics and proficiency in communication, patient evaluation, and procedures.

02/2016 - 02/2016 MEDI2002 Adv Physical Post Graduate Preceptor
Diagnosis

Preparation Hrs: 2, Student Contact Hrs: 10 ; I am a faculty preceptor for an annual lab for the MS1 class during which I instruct small groups (5-6) of first-year medical students throughout the afternoon activity on the intricacies of the pulmonary exam using volunteer patients who have pulmonary abnormalities. The focus of the interaction is on the approach to the patient with lung disease with an emphasis on physical examination abnormalities. My function during the lab is to instruct students on how to approach the physical exam, give feedback on physical examination technique and discuss the reasoning for such abnormalities. In the school of medicine's current curriculum, this is the student's first lab interaction with patients that have known physical examination abnormalities. Each afternoon, the total duration of lab is 2.5 hours with 55 students instructed. I typically serve as preceptor for the lab 4 afternoons every year.

02/2016 - 02/2016 MEDI4170 Internal Medicine Post Graduate Lecturer
Internship Readiness Elective

Preparation Hrs: 6, Student Contact Hrs: 2 ; Title of lecture: "Chest CT for Interns" The goal of this course is to prepare fourth year students for the knowledge, behavior, and skills necessary for internship in Internal Medicine, including diagnosis and management of common medicine topics and proficiency in communication, patient evaluation, and procedures.

02/2016 - 02/2016 SURG4049 Surgical Internship Post Graduate Lecturer
Readiness Elective

Preparation Hrs: 4, Student Contact Hrs: 2 ; Title of lecture: "Chest CT for Interns" The goal of this course is to prepare fourth year students for the knowledge, behavior, and skills necessary for internship in Surgery, including diagnosis and management of common medicine topics and proficiency in communication, patient evaluation, and procedures.

02/2015 - 02/2015 MEDI2002 Adv Physical Post Graduate Preceptor
Diagnosis

Preparation Hrs: 2, Student Contact Hrs: 10 ; I am a faculty preceptor for an annual lab for the MS1 class during which I instruct small groups (5-6) of first-year medical students throughout the afternoon activity on the intricacies of the pulmonary exam using volunteer patients who have pulmonary abnormalities. The focus of the interaction is on the approach to the patient with lung disease with an emphasis on physical examination abnormalities. My function during the lab is to instruct students on how to approach the physical exam, give feedback on physical examination technique and discuss the

reasoning for such abnormalities. In the school of medicine's current curriculum, this is the student's first lab interaction with patients that have known physical examination abnormalities. Each afternoon, the total duration of lab is 2.5 hours with 55 students instructed. I typically serve as preceptor for the lab 4 afternoons every year.

02/2015 - 02/2015 MEDI4170 Internal Medicine Post Graduate Lecturer
Internship Readiness Elective

Preparation Hrs: 5, Student Contact Hrs: 1 ; Title of lecture: "Chest CT for Interns" The goal of this course is to prepare fourth year students for the knowledge, behavior, and skills necessary for internship in Internal Medicine, including diagnosis and management of common medicine topics and proficiency in communication, patient evaluation, and procedures.

02/2015 - 02/2015 SURG4049 Surgical Internship Post Graduate Lecturer
Readiness Elective

Preparation Hrs: 5, Student Contact Hrs: 1 ; Title of lecture: "Chest CT for Interns" The goal of this course is to prepare fourth year students for the knowledge, behavior, and skills necessary for internship in Surgery, including diagnosis and management of common medicine topics and proficiency in communication, patient evaluation, and procedures.

02/2014 - 02/2014 MEDI2002 Adv Physical Post Graduate Preceptor
Diagnosis

Preparation Hrs: 2, Student Contact Hrs: 10 ; I am a faculty preceptor for an annual lab for the MS1 class during which I instruct small groups (5-6) of first-year medical students throughout the afternoon activity on the intricacies of the pulmonary exam using volunteer patients who have pulmonary abnormalities. The focus of the interaction is on the approach to the patient with lung disease with an emphasis on physical examination abnormalities. My function during the lab is to instruct students on how to approach the physical exam, give feedback on physical examination technique and discuss the reasoning for such abnormalities. In the school of medicine's current curriculum, this is the student's first lab interaction with patients that have known physical examination abnormalities. Each afternoon, the total duration of lab is 2.5 hours with 55 students instructed. I typically serve as preceptor for the lab 4 afternoons every year.

02/2014 - 02/2014 MEDI4170 Internal Medicine Post Graduate Lecturer
Internship Readiness Elective

Preparation Hrs: 5, Student Contact Hrs: 1 ; Title of lecture: "Chest CT for Interns" The

goal of this course is to prepare fourth year students for the knowledge, behavior, and skills necessary for internship in Internal Medicine, including diagnosis and management of common medicine topics and proficiency in communication, patient evaluation, and procedures.

02/2014 - 02/2014 SURG4049 Surgical Internship Post Graduate Lecturer
Readiness Elective

Preparation Hrs: 5, Student Contact Hrs: 1 ; Title of lecture: "Chest CT for Interns" The goal of this course is to prepare fourth year students for the knowledge, behavior, and skills necessary for internship in Surgery, including diagnosis and management of common medicine topics and proficiency in communication, patient evaluation, and procedures.

12/2013 - 12/2013 PHAS5033 Clinical Medicine I Graduate Guest Lecturer

Preparation Hrs: 5, Student Contact Hrs: 1 ; Invited guest speaker for Physician Assistant students to provide them with an introduction on IPF. Presentation entitled: "Idiopathic Pulmonary Fibrosis: Overview of Diagnosis & Management"

04/2013 - 04/2013 MEDI4170 Internal Medicine Post Graduate Lecturer
Internship Readiness Elective

Preparation Hrs: 5, Student Contact Hrs: 1 ; Title of lecture: "Chest CT for Interns" The goal of this course is to prepare fourth year students for the knowledge, behavior, and skills necessary for internship in Internal Medicine, including diagnosis and management of common medicine topics and proficiency in communication, patient evaluation, and procedures.

04/2013 - 04/2013 SURG4049 Surgical Internship Post Graduate Lecturer
Readiness Elective

Preparation Hrs: 5, Student Contact Hrs: 1 ; Title of lecture: "Chest CT for Interns" The goal of this course is to prepare fourth year students for the knowledge, behavior, and skills necessary for internship in Surgery, including diagnosis and management of common medicine topics and proficiency in communication, patient evaluation, and procedures.

02/2013 - 02/2013 MEDI2002 Adv Physical Post Graduate Preceptor
Diagnosis

10/2011 - 10/2011 NURS5602 Critical Care Graduate Guest Lecturer
Nursing II

Preparation Hrs: 5, Student Contact Hrs: 1 ; I presented to a group of critical care nursing students a talk on "Diagnosis and Management of Patients with Pulmonary Disorders."

02/2011 - 02/2011 MEDI2002 Adv Physical Post Graduate Preceptor
Diagnosis

Preparation Hrs: 2, Student Contact Hrs: 10 ; I am a faculty preceptor for an annual lab for the MS1 class during which I instruct small groups (5-6) of first-year medical students throughout the afternoon activity on the intricacies of the pulmonary exam using volunteer patients who have pulmonary abnormalities. The focus of the interaction is on the approach to the patient with lung disease with an emphasis on physical examination abnormalities. My function during the lab is to instruct students on how to approach the physical exam, give feedback on physical examination technique and discuss the reasoning for such abnormalities. In the school of medicine's current curriculum, this is the student's first lab interaction with patients that have known physical examination abnormalities. Each afternoon, the total duration of lab is 2.5 hours with 55 students instructed. I typically serve as preceptor for the lab 4 afternoons every year.

10/2010 - 10/2010 NURS5641 Medical-Surgical Graduate Guest Lecturer
Nursing II

Preparation Hrs: 5, Student Contact Hrs: 1 ; I presented to a group of nursing students a talk on "Diagnosis and Management of the Patient with Pulmonary Disease."

08/2010 - Present MEDI2002 Adv Physical Graduate Clinical Faculty
Diagnosis

Preparation Hrs: 5, Student Contact Hrs: 10 ; Annual Pulmonary ACES Course: Pre-clinical teaching using patients with a variety of pulmonary diseases (i.e., very severe chronic obstructive pulmonary disease, pulmonary fibrosis, and/or post-lung transplant) to emphasize physical exam techniques that emphasize the identification and diagnosis of pulmonary problems.

OTHER TEACHING:

Group Instruction

<u>Date</u>	<u>Description</u>	<u>Institution</u>	<u># Students</u>
12/2014 - Present	Multidisciplinary ILD/IPF Conference	UTHSA / VA / UHS	100

Our multidisciplinary ILD conferences, regularly attended by our division's pulmonologists, radiologist Dr. C. Santiago Restrepo, chief of UTHSA Cardiothoracic Radiology, and pathologist, Dr. Sarah Hackman, provide trainees with high-quality, clinically relevant, case-based ILD education. At the request of our pulmonary fellow trainees, I have incorporated high-yield reviews and updates on assorted ILD topics. To further facilitate ongoing learning, I designed a secure cloud-based shared ILD folder of resources for division faculty and fellows, which are continuously updated with latest ILD research studies and clinical practice guidelines.

09/2013 - 09/2013	"Idiopathic Pulmonary Fibrosis: Overview of Diagnosis and Management	UTHSCSA/VA	25
-------------------	--	------------	----

Invited guest speaker for the Pulmonary and Critical Care Fellows' Conference

11/2012 - 11/2012	"Idiopathic Pulmonary Fibrosis" for RT Physician Lecture Series, Guest Speaker	UTHSCSA	50
-------------------	--	---------	----

"Idiopathic Pulmonary Fibrosis" for RT Physician Lecture Series, Guest Speaker

02/2011 - 02/2011	"Introduction to Idiopathic Pulmonary Fibrosis"	UTHSCSA	50
-------------------	---	---------	----

Physician Lecture for Respiratory Therapy Students, Department of Respiratory Care

10/2010 - 10/2010	Pulmonary Medicine Review for Clinical Nurse Specialists	School of Nursing, UTHSCSA	10
-------------------	--	----------------------------	----

Annual series of lectures (3 hours) for Clinical Nurse Specialists in the School of Nursing on a variety of Pulmonary topics: "Commonly Encountered Acute Respiratory Disorders: Keys to Diagnosis and Management."

12/2009 - 12/2009	Clinical Conference: "Acid-Base Disorders"	Southland Hospital, Invercargill, New Zealand	15
-------------------	--	---	----

"Acid-Base Disorders"

11/2009 - 11/2009	Clinical Conference: "Non-Invasive Positive Pressure Ventilation in COPD"	Southland Hospital, Invercargill, New Zealand	15
-------------------	---	---	----

"Non-Invasive Positive Pressure Ventilation in COPD"

10/2008 - 10/2008	Clinical Conference: "UPLIFT: University of Michigan An Anticholinergic Therapy in COPD" <i>"UPLIFT: An Anticholinergic Therapy in COPD"</i>	University of Michigan	25
08/2008 - 08/2008	Clinical Conference: "Chronic Cough" <i>"Chronic Cough"</i>	University of Michigan	25
05/2007 - 05/2007	Respiratory Therapy Teaching Conference <i>"Shock in the ICU: An Often Elusive Diagnosis"</i>	University of Michigan	25
03/2007 - 03/2007	Clinical Journal Club: "Inhaled Corticosteroid Therapy in COPD and Risk of Pneumonia" <i>"Inhaled Corticosteroid Therapy in COPD and Risk of Pneumonia"</i>	University of Michigan	25
02/2007 - 02/2007	Fellows Grand Rounds: "Interesting Cases" <i>"Interesting Cases"</i>	University of Michigan	25
08/2006 - 08/2006	Fellows Grand Rounds: "Interesting Cases" <i>"The Missing Piece: Post-splenectomy Septic Shock"</i>	University of Michigan	25

Individual Instruction

<u>Date</u>	<u>Description</u>	<u>Institution</u>	<u># Students</u>
09/2011 - Present	Mentoring of multiple trainees	University of Texas Health San Antonio, University Hospital, South Texas Veterans Health Care System	26

In addition to teaching activities while on the inpatient services, I also have individually served as mentor for multiple trainees of various disciplines (medicine, nursing, respiratory care, etc.) at various levels (student, intern, resident, fellow, nurse practitioner, physician assistant, etc.). Document quantity and frequency of mentoring, advising, coaching, etc. Differentiate how many and the 'career' level(s) of mentees/advisees (student, faculty, other). List such as mentee(s)' school affiliation and location, and any formal mentoring program name, or state 'informal mentoring program.'

Post Graduate Rotation Supervision

<u>Date</u>	<u>Description</u>	<u>Institution</u>	<u># Students</u>
07/2019 - Present	ILD elective rotation for SAMMC Pulmonary Fellows <i>In 2019, at the request of former San Antonio Military Medical Center (SAMMC) pulmonary fellows, I crafted a new curriculum for an outpatient ILD rotation at my UT Health Physicians' ILD Clinic. This was very well received and enjoyed by the SAMMC pulmonary fellows.</i>	UTHSA	1
11/2010 - Present	General Supervision of Pulmonary & Critical Care Fellows <i>Current and past fellow trainees, 3-4 per year, since 2010.</i>	UTHSCSA / VA / UHS	35

Rotation Student Supervision

<u>Date</u>	<u>Description</u>	<u>Institution</u>	<u># Students</u>
12/2010 - Present	Pulmonary Consultant Inpatient Service Attending <i>8-12 weeks (scheduled), 30+ contact hours per week. Direct supervision and teaching 1-2 Pulmonary/Critical Care Fellows, 2-3 residents, and 2-3 graduate (4th Year Medical) students each week. Topics include the work-up and management of Pulmonary diseases in Medicine, Surgical, Psychiatric, and Obstetrics/Gynecology patients, interpretation of Pulmonary Function Tests, proper technique for chest tube placement (pigtail catheters, Cook catheters, large-bore chest tubes) etc. Since 2010, I have consistently scored 4.50 or greater out of 5.0 on multiple evaluations by trainees. Selected comments include: "Dr. Nambiar provided guidance in our management of the consultations, though he allowed us to arrive at our management plans prior to rounding, giving us on the spot teaching and revision," "Tailored his teaching to appropriate levels for medical students as well as residents; encouraged us to read on relevant topics to supplement what we saw on a daily basis," "Great teacher!," "Wonderful attending physician who I felt cared about trainees and patients," "Dr. Nambiar taught quite a bit and always sent articles to the team. He is a great teacher," "Great teacher - clinician. I learnt a lot during my rotation with him."</i>	University Health System/Audie Murphy Memorial Veterans Hospital	150
11/2010 - Present	Medicine Intensive Care Unit Attending <i>14-18 weeks (scheduled). Direct supervision and teaching 1-2 Pulmonary/Critical Care Fellows, 4-8 residents, 4-8 inters, and 2-4 graduate (4th-Year Medical) students each week.</i>	University Health System and Audie Murphy Memorial Veterans Hospital	350

Teaching rounds consist of concise, yet comprehensive, discussion about new and currently admitted patients, clinically-relevant discussion about diagnoses, differential diagnoses, disease pathophysiology, prognosis, and management strategies. Bedside teaching (7 days/week) includes mechanical ventilation, placement and interpretation of vascular lines, airway management, other procedures (chest tubes, Sengstaken-Bladmore tubes, etc) as well as didactic ICU lectures (30 minutes to 1 hour per day, 5 day/week). (11-22 students). Notably, since 2010, from a sample size of 163 evaluations, I have consistently scored 4.50-5.0 out 5.0 in various areas evaluated such as "Encouraged active house staff participation," "Accommodated teaching to actively incorporate all members of the team," and "Explicitly encouraged further learning." Selected comments including: "Great attending! Always teaching and very informative," "Wonderful attending physician who I felt cared about trainees and patients," "It was excellent working with Dr Nambiar. His teaching related to critical care medicine and overall approach to medicine will always be remembered," "I enjoyed working with Dr. Nambiar. He motivated me to become a better learner as well as a better physician. It is great to be a part of a team where the faculty is available for questions and teaches to our understanding," "Dr. Nambiar is an excellent attending. He is genuinely cares about teaching and his amicable personality makes him easy to work with. As one of the interns told me, "He is the first attending that I have had who actually cared so much about us interns." He displays a passion for teaching and is talented at it. I would recommend keeping the orientation at the beginning of the rotations, the structure of rounds, and the amount of teaching interspersed throughout the day. It is obvious that this well-oiled structure took years to tune up as it runs seamlessly now. No areas of improvement and I would keep everything you are doing. Dr. Nambiar is honestly one of the top 5 attendings I have had during residency and I would not recommend changing anything. Thank you for the wonderful MICU experience."

11/2010 - Present Bronchoscopy Attending University Health System 50
8-16 weeks (scheduled), 10-20 contact hours per week, direct supervision teaching of 2-3 fellows, either internal or external trainees. Topics include: bronchoscopy, bronchoalveolar lavage, cytology and sterile protected specimen brush samples, transbronchial and endobronchial biopsies, lymph node needle biopsies, cryotherapy, brachytherapy, tracheal/bronchial stent placement, tracheal/bronchial balloon dilation, etc (1-2 students)

11/2010 - Present Pulmonary Clinic Attending University Health Systems (Downtown Clinic) 50
1/2 day clinic per week during consult rotation, 8-14 weeks, 5-6 contact hours/week. Direct supervision and teaching 3 Pulmonary/Critical Care Fellows, 2-3 Internal Medicine Residents, 2-3 graduate (4th Year Medical School)students. (3-9 students)

RESEARCH

EXPERTISE:

Interstitial lung diseases (ILD) - Since joining the University of Texas Health San Antonio (UTHSA) Division of Pulmonary and Critical Care Medicine in 2010, my service-related clinical, research, and teaching passion is on interstitial lung diseases (ILD), specifically idiopathic pulmonary fibrosis (IPF). In 2012, I became the founding director of the UTHSA Center for ILD. In 2015, our ILD program was recognized by the Pulmonary Fibrosis Foundation (PFF) as a Care Center Network Site, or an ILD Center of Excellence, currently 1 of 68 centers in the U.S, 1 of 5 in Texas, and the only one in South Texas. Clinically-focused initiatives include the founding of the UT Medicine ILD clinic, bimonthly multidisciplinary ILD conference, and CT-ILD protocols in collaboration with our radiology group. Research efforts include serving as either principal or co-investigator for multiple institutional or industry-sponsored studies, including the landmark ASCEND and INBUILD trials that have led to FDA approvals of pirfenidone, the first ever drug therapy for IPF, and nintedanib, the first ever drug therapy for progressive fibrosing ILDs. Educational activities include multiple invited presentations on ILD and IPF at the international, national, and regional levels to interdisciplinary trainees at all levels. In 2019, I co-chaired the biennial PFF Summit held in San Antonio. I also serve our community as the medical director for the local pulmonary fibrosis support group. More recently, I have collaborated with my geriatric colleagues from UTHSA, Mayo Clinic in Rochester, MN, and Wake Forest University on senescence in IPF, including having performed the first-in-human, open-label and randomized controlled, pilot studies of senolytics in IPF.

PROJECTS:

Clinical Research

- 06/2020- Present Pulmonary fibrosis in post-COVID-19 survivors, Determine the prevalence, characteristics, risk factors, and severity of pulmonary fibrosis after surviving COVID-19 through a prospectively enrolled VA convalescent program. Also to assess the safety and efficacy of currently available antifibrotic therapies for the treatment of post-C19 PF in a prospective, randomized controlled trial.
- 11/2019- Present ILD Diagnostic Trajectories Following Multidisciplinary Discussion, To review of center's ILD conference cases focusing on change of diagnosis and potential implications after multidisciplinary discussion. In collaboration with Drs. Amati (Milan, Italy) and Marcos Restrepo (PCCM faculty).
- 12/2018- Present The Role of Bronchoalveolar Lavage in Idiopathic Pulmonary Fibrosis, Prospective pilot study on the utility of bronchoalveolar lavage to differentiate IPF from chronic hypersensitivity pneumonitis.

Co-Investigator

- 02/2020- Present Diagnostic utility of bedside lung ultrasound in interstitial lung disease, We will be conducting a pilot study on the use of ultrasound in the diagnosis of interstitial lung diseases in collaboration with Drs. Choudhury (PCCM fellow), Proud (PCCM faculty), and Soni (Medicine/PCCM faculty).

Collaborative Research

- 05/2015- Present SIMPLE-IPF research grant application to the NIH/NHLBI, I was invited by the principal investigator, Dr. Ganesh Raghu from the University of Washington, to collaborate on this submitted NIH/NHLBI research grant application. This study is titled "Studying the Impact of Altering the Microbial and Immune Response: A Pragmatic Approach to IPF (SIMPLE-IPF). This will be a multicenter, 2x2 factorial, placebo-controlled, randomized clinical trial evaluating the safety and efficacy of doxycycline-alone, NAC-alone, combination of doxycycline & NAC compared to placebo in patients with IPF.
- 09/2014- Present Pulmonary Trails Cooperative (PTC), Given our center's expertise in recruiting a large number of ILD subjects and creating a functional satellite network in previous clinical trials, I was invited by Dr. Fernando Martinez at Weill Cornell Medical Center in New York and Dr. MeiLan Han at the University of Michigan to participate as one of the clinical centers in this NHLBI initiative to carry out pragmatic, phase 2 and 3 clinical trials.

Investigator Initiated Projects

- 05/2013- Present The Safety and Effectiveness of Mycophenolate Mofetil in IPF, Mycophenolate mofetil is a potent immunosuppressive drug which has both anti-inflammatory and anti-fibrotic effects. There is little data regarding its clinical utility in patients with idiopathic pulmonary fibrosis (IPF). This retrospective observational study is aimed at determining whether mycophenolate is both safe and effective in patients with IPF compared to those with IPF patients treated with other therapies, patients with IPF not any specific therapy, and those patients with autoimmune-related interstitial lung disease.

Other

- 01/2015- Evidence-Based Critical Care book chapters, I was invited by the Editor-in-chief,
04/2015 Dr. Robert Hyzy, to author two chapters in his Evidence-Based Critical Care: A Case-Based Approach textbook soon to be published. Along with two fellows, we wrote chapters on "Acute Lower Gastrointestinal Bleeding" and "Thrombotic Thrombocytopenia Purpura."

Pilot Research

- 10/2010- Present Pilot Study of Pyridinoline, A Novel IPF Biomarker, This pilot study is aimed at identifying a novel biomarker in idiopathic pulmonary fibrosis called pyridinoline in the urine and blood. If validated, this novel biomarker may help more accurately diagnose, predict disease course, predict acute exacerbations, monitor for disease progression, and assess clinical response to therapy.

Research Article

- 05/2020- Present Pulmonary-urolologic disease: a review of diagnoses and management strategies, Invited to participate in this review article along with Dr. Deepak Pruthi, a urologist with UT Health Physicians, University Hospital, and South Texas VA Health Care System. Manuscript in process.
- 03/2015- 07/2015 Diagnosis and Management of Sarcoidosis, Invited review article from the American Family Physician. Co-authors: Natalia Soto-Gomez, MD and Jay I. Peters, MD.

PUBLICATIONS: (*' indicates Peer Reviewed)

Abstract

1. Shapera S, Moua T, Nambiar AM, Morrison LD, Kolb M, Schlenker-Herweg R, Conoscenti CS, Goeldner R-G, Rohr KB, Stowasser S, Brown KK. Efficacy and safety of nintedanib in US/Canadian patients with progressive fibrosing interstitial lung diseases: further analyses of the INBUILD trial 2020 Oct. (CHEST).
2. Tam W, Islam T, Maselli DJ, Nambiar AM. The Role of Bilateral Bronchoalveolar Lavage in Idiopathic Pulmonary Fibrosis 2020 May. (American Journal of Respiratory and Critical Care Medicine).
3. Villalpando J, Peters JI, Nambiar AM. No Prednisone, No Problem: Use of Solu-Medrol in ILD 2020 May. (American Journal of Respiratory and Critical Care Medicine; vol. 201, no. A1481).
4. Stephens B, Choudhury R, Nambiar AM. Chronic Hypersensitivity Pneumonitis: The Pulmonary "Mask-Erader" 2020 May. (American Journal of Respiratory and Critical Care Medicine; vol. 201, no. A1447).
5. Amati F, Restrepo MI, Aliberti S, Blasi F, Nambiar AM. Diagnostic Trajectories of Interstitial Lung Disease After Implementation of a Multidisciplinary Discussion Team Meeting 2020 May. (American Journal of Respiratory and Critical Care Medicine; vol. 201, no. A3359).
6. Jamie N Justice, Anoop M Nambiar, Tamar Tchkonina, Nathan K LeBrasseur, Nicolas Musi, Stephen B Kritchevsky, and James L Kirkland. Cellular Senescence as a Therapeutic Target For Geroscience-Guided Clinical Trials 2019 Nov. (Innovation Aging; vol. 3, no. S811).
7. Anoop Nambiar, Jamie Justice, Tamar Tchkonina, Nathan Lebrasseur, Rodolfo Pascual, Shahrukh Hashmi, Larissa Prata, Michal Masternak, Nicolas Musi, Stephen Kritchevsky, James Kirkland. Late Breaking Abstract - Evaluating the feasibility, safety, and efficacy of senolytics in idiopathic pulmonary fibrosis 2019 Sep. (European Respiratory Journal; vol. 54, no. OA244).

8. Saikumar HP, Maselli DJ, Nambiar AM. With Child-A Case of Antisynthetase Syndrome in Pregnancy 2019 May. (American Journal of Respiratory and Critical Care Medicine; vol. 195, no. A3403).
9. Nambiar AM, Justice J, Pascual RM, Tchkonja T, LeBrasseur N, Kirkland JL, Musi N, Kritchevsky S. Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: an Open-Label Pilot Study of Dasatinib and Quercetin 2018 Oct. (CHEST International Conference).
10. Birdwell A, Rayapudi M, Johnson S, Nambiar AM. Debunking and Debulking a Diagnosis of Asthma via Influenza 2018 Oct. (CHEST 2018).
11. Abdalla M, De Hoyos P, Nambiar AM. If the Stent Fits, Place It: A Novel Approach To The Treatment of Non-Operative Pulmonary Artery Angiosarcoma 2018 Oct. (CHEST; vol. 154, no. 4).
12. Castaneda-Nerio JC, Nambiar AM, Restrepo CS. Dendiform Pulmonary Ossification in Interstitial Lung Disease 2017 May. (American Thoracic Society International Conference 2017).
13. Dreyfuss Z, Nambiar AM. Clogging the Pipes 2016 Oct. (CHEST International Conference 2016).
14. L.B. Tolle, N. Tayob, A. Nambiar, S.L. Schmidt, A. Flint, A. Lagstein, J.L. Myers, L.A. Schmidt, B. Gross, E. Kazerooni, B. Sundaram, A. Chughtai, G.B. Toews, F.J. Martinez, K.R. Flaherty. The Role Of High-Resolution CT Patterns In Prognosticating IPF Presented at ATS 2014 International Conference in San Diego, CA: 2014 May. (ATS International Conference - 2014).
15. Schmidt SL, Sundaram B, Tayob N, Han MK, Nambiar AM, Kazerooni EA, Gross BH, Chughtai A, Myers JL, Flint A, Murray S, Toews GB, Martinez FJ, Flaherty KR. Longitudinal Changes in the Composite Physiologic Index and Pulmonary Function in patients with Idiopathic Pulmonary Fibrosis and Emphysema. 2010 May. (ATS International Conference - 2010).
16. Nambiar A, Han MK, Schmidt S, Myers JL, Lagstein A, Flint A, Gross BH, Kazerooni EA, Sundaram B, Chughtai A, Toews GB, Martinez FJ, Flaherty KR. Change in the composite physiologic index predicts mortality in patients with IPF. 2009 May. (ATS International Conference - 2009).
17. Schmidt S, Nambiar A, Han MK, Myers JL, Lagstein A, Flint A, Gross BH, Kazerooni EA, Sundaram B, Chughtai A, Toews GB, Martinez FJ, Flaherty KR. Does the composite physiology score improve the correlation to the six-minute walk test over individual pulmonary function tests in patients with idiopathic pulmonary fibrosis? 2009 May. (ATS International Conference - 2009).

18. Ohtani Y, Nambiar A, Schmidt S, Han MK, Kazerooni EA, Myers JL, Gross BH, Sundaram B, Inase N, Yoshizawa Y, Toews GB, Martinez FJ, Flaherty KR, Flint A. Idiopathic nonspecific interstitial pneumonia: prognostic value of hallwalk distance and changes in physiology 2009 May. ([ATS International Conference - 2009](#)).

Book Chapter

1. Amalakuhan B, Nambiar AM. Diagnosis and Management of Thrombotic Thrombocytopenic Purpura In: Hyzy RC (Editor), McSparron J (Editor). Evidence-Based Critical Care: A Case Study Approach, 2nd ed. 2020 Edition. Springer; 2020.
2. Abedi A, Nambiar AM. Acute Lower Gastrointestinal Bleeding In: Hyzy RC, McSparron J. Evidence-Based Critical Care: A Case Study Approach, 2nd ed. 2020 Edition. Springer; 2020.
3. Amalakuhan B, Nambiar AM. Diagnosis and Management of Thrombotic Thrombocytopenic Purpura In: Robert C. Hyzy (Editor). Evidence-Based Critical Care: A Case Study Approach. Springer; 1st ed. 2017 edition; 2018.
4. Abedi A, Nambiar AM. Acute Lower Gastrointestinal Bleeding In: Evidence-Based Critical Care: A Case Study Approach. Springer; 1st ed. 2017 edition; 2017.

Editorial

1. Velez MI, Nambiar AM. Combination pirfenidone and inhaled N-acetylcysteine therapy for IPF: Does it take these two to tango? [Respirology](#) 2015 Feb
- * 2. Nambiar AM. Procalcitonin in Acute Exacerbations of Interstitial Pneumonia: Another Tool in the Toolbox? [Respirology](#) 2013 Apr;18(3):389-390.

Electronic/Web Publication

- * 1. Kulkarni T, Haywood A, Nambiar AM. Nintedanib-a potential new therapy for systemic sclerosis-associated interstitial lung disease 2020 Apr.
2. Nambiar A, Hyzy RC. Endotracheal tube management and complications - 2009 Waltham, MA: UpToDate online; 2009
3. Nambiar A, Hyzy RC. Extubation Management - 2009 Waltham, MA: UpToDate online; 2009
4. Nambiar A, Hyzy RC. Endotracheal tube management and complications - 2008 Waltham, MA: UpToDate online; 2008

5. Nambiar A. Extubation Management - 2008 Waltham, MA: UpToDate online; 2008
6. Nambiar A, Hyzy RC. Permissive hypercapnic ventilation - 2008 Waltham, MA: UpToDate online; 2008
7. Nambiar A, Hyzy RC. Endotracheal tube management and complications - 2007 Waltham, MA: UpToDate online; 2007
8. Nambiar A, Hyzy RC. Permissive hypercapnic ventilation - 2007 Waltham, MA: UpToDate online; 2007

Journal Article

- * 1. Tam WS, Islam T, Nambiar AM. Hypersensitivity Pneumonitis (Including Environmental Assessment): Diagnosis and Management Current Pulmonology Reports 2019 Dec;8(4):131-138.
- * 2. Flaherty KR1, Wells AU1, Cottin V1, Devaraj A1, Walsh SLF1, Inoue Y1, Richeldi L1, Kolb M1, Tetzlaff K1, Stowasser S1, Coeck C1, Clerisme-Beaty E1, Rosenstock B1, Quaresma M1, Haeufel T1, Goeldner RG1, Schlenker-Herceg R1, Brown KK1; INBUILD Trial Investigators including Nambiar AM.. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases New England Journal of Medicine 2019 Sep;318(18):1718-1727.
- 3. Jamie N. Justice Anoop M. Nambiar Tamar Tchkonina Nathan K. LeBrasseur Rodolfo Pascual Shahrukh K. Hashmi Larissa Prata Michal M. Masternak Stephen B. Kritchevsky Nicolas Musi James L. Kirkland. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study EBioMedicine 2019 Jan
- * 4. Vincent Cottin Nikhil A. Hirani David L. Hotchkin Anoop M. Nambiar Takashi Ogura María Otaola Dirk Skowasch Jong Sun Park Hataya K. Poonyagariyagorn Wim Wuyts Athol U. Wells. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases European Respiratory Review 2018 Dec
- * 5. Joana Alves, Emine Alp, Despoina Koulenti, Zhongheng Zhang, Stephan Ehrmann, Stijn Blot, Matteo Bassetti, Andrew Conway-Morris, Rosa Reina, Enrique Teran, Candela Sole-Lleonart, Maria Ruiz-Rodríguez, Jordi Rello, and the SANEME 2 Study Investigators (Anoop Nambiar, collaborator). Nebulization of antimicrobial agents in mechanically ventilated adults in 2017: an international cross-sectional survey European Journal of Clinical Microbiology 2018 Apr
- * 6. Salisbury ML, Tolle LB, Xia M, Murray S, Tayob N, Nambiar AM, Schmidt SL, Lagstein A, Myers JL, Gross BH, Kazerooni EA, Sundaram B, Chughtai AR, Martinez FJ, Flaherty KR.. Possible UIP pattern on high-resolution

computed tomography is associated with better survival than definite UIP in IPF patients. Respiratory Medicine 2017 Oct

7. Walsh SLF1, Maher TM2, Kolb M3, Poletti V4,5, Nusser R6, Richeldi L7, Vancheri C8, Wilsher ML9, Antoniou KM10, Behr J11, Bendstrup E5, Brown K12, Calandriello L13, Corte TJ14, Cottin V15, Crestani B16, Flaherty K17, Glaspole I18, Grutters J19, Inoue Y20, Kokosi M21, Kondoh Y22, Kouranos V21, Kreuter M23, Johannson K24, Judge E25, Ley B26, Margaritopoulos G21, Martinez FJ27, Molina-Molina M28, Morais A29, Nunes H30, Raghu G31, Ryerson CJ32, Selman M33, Spagnolo P34, Taniguchi H22, Tomassetti S4, Valeyre D30, Wijsenbeek M35, Wuyts W36, Hansell D37, Wells A38; IPF Project Consortium...Nambiar A (collaborator). Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. European Respiratory Journal 2017 Aug;50(2)
- * 8. Nambiar AM, Anzueto AR, Peters JI. Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis PLoS ONE 2017 Apr;12(4)
- * 9. Soto-Gomez N, Peters JI, Nambiar AM. Diagnosis and Management of Sarcoidosis. Am Fam Physician 2016 May;93(10):840-848.
- * 10. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group.. A Phase 3 Trial Of Pirfenidone In Patients With Idiopathic Pulmonary Fibrosis N Engl J Med 2014 May;370(22):2083-2092.
- * 11. Maselli DJ, Fernandez J, Whong CY, Echevarria K, Nambiar AM, Anzueto AR, Restrepo MI.. Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia Infect Drug Resist 2012 Feb;5:43-51.
12. Schmidt SL, Nambiar AM, Tayob N, Sundaram B, Han MK, Gross BH, Kazerooni EA, Chughtai AR, Lagstein A, Myers JL, Murray S, Toews GB, Martinez FJ, Flaherty KR. Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J 2011 Jul;38(1):176-183.

PRESENTATIONS:

05/2020 Use of DLCO in Interstitial Lung Disease, nnd Medical Educational Webinar, nnd Medical (Invited Speaker)

Details: I was invited to speak about the role of diffusion capacity (DLCO) in the diagnosis and management of interstitial lung disease (ILD).

04/2020 Therapeutics: senolytics and senomorphs, NIH/NIA Think Tank meeting on senolytics and senomorphics, National Institutes of Health, National Institute of Aging (Co-Presenter)

Details: Invited to participate and present at a web-based meeting to define important areas of development for a potential NIH Common Fund program on Cellular Senescence and Senolytics

11/2019 Senolytics Put to the Test for IPF in a Clinical Trial, Pulmonary Fibrosis Foundation Summit 2019, Senescence session, Pulmonary Fibrosis Foundation, San Antonio, TX (Invited Speaker)

Details: Attendees: 450

10/2019 Clinical Significance of DLCO Testing in IPF/ILD, CHEST International Conference 2019, Session title: The Clinical Use of DLCO Testing in the Diagnosis and Management of Lung Disease, American College of Chest Physicians, New Orleans, LA (Invited Speaker)

Details: Attendees: 175; I discussed the clinical significance of proper diffusion capacity testing in the evaluation and care of patients with interstitial lung diseases (ILD), such as idiopathic pulmonary fibrosis (IPF).

10/2019 Improving time to diagnosis in IPF: is there a role for genomics?, 2019 CHEST International Conference, Virtual Patient Tour, American College of Chest Physicians, New Orleans, LA (Co-Presenter)

Details: I was invited, co-created, and co-presented this virtual patient tour at the 2019 CHEST International Conference on educating attendees through virtual cases on the role of genomics in the diagnosis of ILD and IPF.

10/2019 Initiating the right ILD treatment approach, 2019 CHEST International Conference, Podcast, ReachMD, New Orleans, LA (Invited Speaker)

Details: I was invited to be the host presenter for this podcast aimed at educating pulmonary physicians on exciting news on ILD treatments at the 2019 CHEST International Conference. Link: <https://reachmd.com/programs/deep-breaths-updates-chest/initiating-the-right-interstitial-lung-disease-treatment-approach/11014/>.

09/2019 Evaluating the feasibility, safety, and efficacy of senolytics in idiopathic pulmonary fibrosis, European Respiratory Society International Congress 2019, Late Breaking Abstract Session, European Respiratory Society, Madrid, Spain (Invited Speaker)

Details: Attendees: 750; one of a few selected abstracts to be presented at the ERS 2019 Late Breaking Abstract Session.

08/2019 Teamwork and Interdisciplinary Collaboration in Interstitial Lung Disease, South Texas Area Health Education Center Scholars Program Workshop, South Texas Area Health Education Center, San Antonio, TX (Invited Speaker)

Details: Attendees: 75; Goal: to highlight the importance of medicine requiring a team working collaboratively to care for patients in a positive manner and/or healthcare practice in the future; My vision for future healthcare practices; Primary focus of the All Scholars Workshop is interprofessional education (IPE) - We seek to reinforce the 4 domains of IPE of 1) values/ethics, 2) roles and responsibilities, 3) interprofessional communication, 4) teams and teamwork.

08/2019 Clinical Experience with Senolytic Activity of a Combination of Dasatinib and Quercetin, NIH/NIA Workshop on Repurposing Drugs or Dietary Supplements for their Senolytic or Senomorphic Effects: Considerations for Clinical Trials, National Institute of Aging, National Institutes of Health, Bethesda, MD (Invited Speaker)

Details: Attendees: 25 from around the U.S. and world; Discussed: 1) Subtypes of senescent cells in different tissues and potential types of senolytics (SLs) and senomorphics; 2) Mechanism of senolytic activity of specific drugs and supplements, their potential role in treatment or prevention of disease and effects on other mechanisms besides cell senescence, including effects in non-senescent cells; 3) Modulators of the senescence-associated secretory phenotype, their mechanism of action and potential role in treatment or prevention of disease; 4) Resources for planning trials; 5) Special considerations for trials on effects of senolytics/senomorphics.

07/2019 Idiopathic Pulmonary Fibrosis: What It Is and Why You Should Care, 7th U.S.-Mexico Regional Binational Health Conference about Diseases and Emergencies Update, UT Health Regional Campus Laredo, Texas Department of State Health Services, Office of Public Health, and Area Health Education Center of the Mid Rio Grande Border Area, Laredo, TX (Invited Speaker)

Details: Attendees: 175; The purpose of this annual conference is to offer current information, on medical issues affecting the region. Respiratory/Pulmonary Diseases is a topic of extreme interest to medical providers in the region, including the medical providers from Tamaulipas, Mexico who always make it a point to attend on an annual basis. We know that you have done extensive research on this topic and we would very appreciate your consideration of our invitation.

07/2019 Idiopathic Interstitial Lung Diseases: Is a Cause Truly Unidentifiable?, Pulmonary Fibrosis Foundation Disease Education Webinar, Pulmonary Fibrosis Foundation (Invited Speaker)

Details: Invited to present a live online webinar to discuss the various idiopathic interstitial pneumonias from diagnosis to treatment. This webinar was recorded and is available on-demand at: <https://www.pulmonaryfibrosis.org/life-with-pf/pff-educational-resources/webinars/idiopathic-interstitial-lung-diseases-when-a-cause-is-truly-unidentifiable>.

06/2019 ILD & IPF: Perspective From an Academic Pulmonologist, Veracyte New Hire Training, Veracyte, San Francisco, CA (Sole Presenter)

Details: Invited sole speaker by Veracyte to discuss diagnosis, treatment, natural history, and prognosis of ILD & IPF from an academic pulmonologist's perspective.

06/2019 When is a Cough not just a Cough?, Medical Grand Rounds, Department of Medicine, University of Maryland Medical Center (Midtown Campus), Baltimore, MD (Invited Speaker)

Details: Sponsored by the France Foundation PILOT for IPF program

05/2019 Senolytics in Idiopathic Pulmonary Fibrosis: Preliminary Results From a First-in-human, Open-label, Pilot Study, American Thoracic Society International Conference 2019, American Thoracic Society, Dallas, TX (Invited Speaker)

Details: Attendees: 175

05/2019 Real World Challenges in the Diagnosis of IPF, American Thoracic Society International Conference 2019, Meet The Professor Session, American Thoracic Society, Dallas, TX (Invited Speaker)

Details: Attendees: 25

11/2018 Senolytics in IPF, Pepper Center Institutional Advisory Board Meeting, San Antonio, TX (Invited Speaker)

Details: Present and former scholars and pilot awardees present their research to get input and foster collaboration. This year, we also plan to invite people with leadership roles at SOM and university, hoping to get their support and advice on center renewal, due in 2019.

10/2018 Idiopathic pulmonary fibrosis: a silent killer, 34th Annual Update in Medicine Conference, Area Health Education Center of the Mid Rio Grande Border Area of Texas, Inc. & The Webb-Zapata-Jim Hogg County Medical Society, Laredo, TX (Invited Speaker)

Details: The goal of the Annual Update in Medicine is to provide state of the art information for the local health care professionals about the medical conditions that are of primary concern in their practice. The Annual Update includes a forum that provides the latest medical information about treatment, diagnostic modalities, and ongoing research in an environment conducive to group discussion and the interchange of ideas. This conference provides information to healthcare professionals to improve the overall quality of health care in this community.

08/2018 Senolytics in IPF, Pepper Center External Advisory Board Meeting, San Antonio, TX (Invited Speaker)

Details: Invited by Drs. Clark and Kasinath to talk about our pilot study funded by the PECS.

06/2018 A New Era in the Interdisciplinary Care of Patients with IPF, 47th Annual TSRC State

Convention and Exhibition, Texas Society of Respiratory Care, New Braunfels, TX
(Invited Speaker)

05/2018 Real World Challenges in the Diagnosis of Idiopathic Pulmonary Fibrosis, American Thoracic Society International Conference 2018, Meet the Professor Session, American Thoracic Society, San Diego, CA (Invited Speaker)

Details: Attendees: 25

03/2018 A New Era in Idiopathic Pulmonary Fibrosis, Asthma, Allergy, and Pulmonary Diseases Conference: 'Every Breath You Take', Coastal Bend Health Educational Center, Texas A&M University, Corpus Christi, TX (Invited Speaker)

03/2018 ILD and IPF for the Medicine Resident, Internal Medicine Noon Conference, UTHSCSA, San Antonio, TX (Invited Speaker)

03/2018 A New Era in the Diagnosis and Management of Idiopathic Pulmonary Fibrosis, 23rd Annual Respiratory Care Symposium, UTHSCSA Department of Respiratory Care, San Antonio, TX (Invited Speaker)

10/2017 Advances in Interstitial Lung Disease -- Power in Numbers, 5th Annual Transplant Symposium: "A Multidisciplinary Approach: Innovation in Transplantation", Lung Transplant, Memorial Hermann Health System, Houston, TX (Invited Speaker)

10/2017 ILD Centers of Excellence Come of Age, CHEST International Conference, American College of Chest Physicians, Toronto, Canada (Invited Speaker)

09/2017 The Use of Senolytics in Older Patients with Idiopathic Pulmonary Fibrosis, Pepper Center Annual Retreat, Division of Geriatrics, Department of Medicine, UT Health San Antonio and South Texas Veterans Health Care System, San Antonio, TX (Invited Speaker)

05/2017 Real World Challenges in the Diagnosis of Idiopathic Pulmonary Fibrosis, American Thoracic Society International Conference 2017, Meet the Professor Session, American Thoracic Society, Washington, DC (Invited Speaker)

Details: Attendees: 25

04/2017 ILD and IPF for the Medicine Resident, Internal Medicine Noon Conference, Department of Medicine, UT Health San Antonio, San Antonio, TX (Invited Speaker)

12/2016 ILDs: What Are They and Why Do You Need To Know About Them?, 2016 Texas Society for Respiratory Care-Alamo District Conference, Texas Society for Respiratory Care, San Antonio, TX (Invited Speaker)

12/2016 Interstitial Lung Diseases and Important Surgical Issues, City-wide Cardiothoracic

Surgery Grand Rounds, Cardiothoracic Surgery, UTHSCSA, San Antonio, TX (Invited Speaker)

Details: I was invited by the Department of Cardiothoracic Surgery to speak about ILD and IPF at their city-wide grand rounds. This was a city/regional conference. Attendees: 15.

09/2016 2016 Overview of Idiopathic Pulmonary Fibrosis, Fellows' Conference, Division of Pulmonary Diseases and Critical Care Medicine, UTHSCSA, San Antonio, TX (Invited Speaker)

08/2016 All That is UIP is Not IPF, 69th Annual KOPPA Conference State of the Art Lung Updates, Baylor Scott & White Health and University of Texas Medical Branch, Hunt, TX (Invited Speaker)

Details: Regional/state-wide conference, attendees: 50

04/2016 A New Era in ILD and IPF, Annual Aging Conference: The Stay Healthier Longer Series, UTHSCSA Regional Campus at Laredo, Laredo, TX (Keynote Speaker)

Details: Regional presentation; only speaker; 250 attendees Annual conference since 2010, focus on how to stay healthier longer, audience included community participants and healthcare professionals, free community event, program held on a Saturday morning included exhibits and demonstrations from 8-10am followed by keynote address with Q&A for a total of 1.5 hours.

03/2016 A New Era in the Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis, 21st Annual Respiratory Care Symposium, Department of Respiratory Care, UTHSCSA, San Antonio, TX (Invited Speaker)

Details: City/regional presentation; 200 attendees Location: Pearl Stables on Pearl Parkway. 12 CEUs are available upon completion of a program evaluation.

02/2016 The Dawn of a New Era in the Treatment of Idiopathic Pulmonary Fibrosis, Pulmonology Conference of South Texas, Acuity Hospital of South Texas, San Antonio, TX (Invited Speaker)

Details: City/regional presentation; 20 attendees. This one day Conference includes lectures concerning different aspects of Lung Disease including the latest treatments and is intended for practicing physicians – Pulmonologists, Internal Medicine and Thoracic Surgeons. The emphasis is on current and relevant information with an interest in Clinical Pulmonology. Interaction and discussion with the Faculty is encouraged to promote the flow and utilization of the latest ideas in this profession to maintain the high standard to benefit patient care. Dannemiller Corporation designates this live education activity for a maximum of 6.75 AMA PRA Category 1 Credit(s).TM

12/2015 All That is UIP is NOT IPF, Department of Pathology Grand Rounds, UTHSCSA, San Antonio, TX (Co-Presenter)

- 10/2015 Pulmonary Fibrosis: What Every Healthcare Professional Should Know, 31st Annual Medicine Update Conference, South Coastal Area Health Education Center, Laredo, TX (Invited Speaker)
Details: Regional presentation, 250 attendees composed of primary care physicians, hospitalists, first responders, nurses, physician assistants, and other interested allied healthcare professions.
- 08/2015 Scleroderma and Systemic Sclerosis Related Interstitial Lung Disease, Monthly group meeting, Scleroderma Support Group of San Antonio, Scleroderma Foundation, San Antonio, TX (Invited Speaker)
Details: I was invited by the group to talk about scleroderma and systemic sclerosis related interstitial lung disease. The talk was well-received by the 10 attendees.
- 07/2015 New Hope for Patients Suffering from Idiopathic Pulmonary Fibrosis, 44th Annual TSRC State Convention and Exhibition, Texas Society of Respiratory Care, Houston, TX (Invited Speaker)
Details: Regional/statewide presentation, 150+ attendees
- 06/2015 A New Era in the Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis, Medicine Grand Rounds, Department of Medicine, UTHSCSA, San Antonio, TX (Invited Speaker)
Details: To an audience of about 75 students, residents, fellows, and faculty within the Department of Medicine, I discussed a case, background, diagnosis, and comprehensive management of patients with IPF.
- 04/2015 "The Treatment of Idiopathic Pulmonary Fibrosis: You Don't Know Where You're Going If You Don't Know Where You've Been", Medicine Research Seminar, Department of Medicine, UTHSCSA, San Antonio, TX (Invited Speaker)
Details: To an audience of about 100 students and faculty in the Department of Medicine, I discussed the past, present, and future treatment of IPF.
- 03/2015 A New Era in the Treatment of Idiopathic Pulmonary Fibrosis, 20th Annual Respiratory Care Symposium, Department of Respiratory Care, UTHSCSA, San Antonio, TX (Invited Speaker)
Details: Local/regional presentation, nearly 100 respiratory care faculty and student attendees
- 12/2014 "The Lung, Liver, and Gut: An Unusual Link", Pathology Grand Rounds: Clinical-radiologic-pathologic Conference, Department of Pathology, UTHSCSA, San Antonio, TX (Panel)
Details: I was amongst 2 other invited guest speakers (Dr. Jay Peters and Dr. Carlos S. Restrepo) to discuss airway-centered diseases at the clinical-radiologic-pathologic conference. My specific case was one of a patient presumptively diagnosed with IPF

and also celiac disease. She underwent a surgical lung biopsy that was not consistent with UIP/IPF, but, in fact, airway-centered fibrosis suspicious for celiac disease-associated ILD.

10/2014 Idiopathic Pulmonary Fibrosis: Tackling the Challenges of an Accurate Diagnosis and Multidisciplinary Management, 20th Annual Alamo District-TSRC Seminar, Alamo District Board, Texas Society of Respiratory Care, San Antonio, TX (Invited Speaker)

Details: Local/regional presentation, 150+ attendees

10/2014 Idiopathic Pulmonary Fibrosis: Fall 2014 Update on Diagnosis & Management, Fellows Conference, Division of Pulmonary & Critical Care, Dept of Internal Medicine, UTHSCSA, San Antonio, TX (Invited Speaker)

Details: 50 attendees

10/2014 New Hope for Patients Suffering from Idiopathic Pulmonary Fibrosis, 30th Annual Update in Medicine Conference, The Area Health Education Center, The Mid Rio Grande Border of Texas, Inc. and The Webb-Zapata-Jim Hogg County Medical Society, Laredo, TX (Invited Speaker)

Details: Regional presentation, 100+ attendees

05/2014 Idiopathic Pulmonary Fibrosis: Overview of IPF and the Important Role of the Respiratory Therapist, TSRC 43rd Annual State Convention and Exhibition, Texas Society of Respiratory Care, Texas Society of Respiratory Care, San Antonio, TX (Invited Speaker)

Details: Regional presentation, 150+ attendees

10/2013 Idiopathic Pulmonary Fibrosis: Overview of IPF and the Important Role of the Respiratory Therapist, 19th Annual Alamo District-TSRC Seminar, Alamo District Board, Texas Society of Respiratory Care, San Antonio, TX (Invited Speaker)

Details: Local presentation, 100 attendees

09/2013 Idiopathic Pulmonary Fibrosis: Overview of Diagnosis & Management, Fellows Conference, Division of Pulmonary & Critical Care, Dept of Internal Medicine, UTHSCSA, San Antonio, TX (Invited Speaker)

Details: Local presentation, 40 attendees

05/2012 Idiopathic Pulmonary Fibrosis: Tackling the Challenges of an Accurate Diagnosis and Multidisciplinary Management, SAMMC Medicine Grand Rounds, Department of Medicine, San Antonio Military Medical Center, San Antonio, TX (Invited Speaker)

Details: Local presentation, 75 attendees

01/2012 Idiopathic Pulmonary Fibrosis: A 2011 Update on Management Strategies, UTHSCSA Medicine Grand Rounds, Medicine, UTHSCSA, San Antonio, TX (Invited Speaker)

Details: Local presentation, 75 attendees

03/2011 Management Strategies for Idiopathic Pulmonary Fibrosis, 16th Annual Respiratory Care Symposium Pulmonary Medicine Update, Department of Respiratory Care, University of Texas Health Science Center at San Antonio, San Antonio, TX (Invited Speaker)

Details: Regional presentation, 125 Attendees

05/2010 Longitudinal Changes in the Composite Physiologic Index and Pulmonary Function in patients with Idiopathic Pulmonary Fibrosis and Emphysema., American Thoracic Society International Conference, New Orleans, LA (Co-Author)

Details: International presentation, poster discussion, 100+ attendees

05/2009 Change in the composite physiologic index predicts mortality in patients with IPF., American Thoracic Society International Conference, San Diego, CA (Invited Speaker)

Details: International presentation, poster discussion, 100 attendees

05/2009 Does the composite physiology score improve the correlation to the six-minute walk test over individual pulmonary functions tests in patients with idiopathic pulmonary fibrosis?, American Thoracic Society International Conference, San Diego, CA (Co-Author)

Details: International presentation, 100 attendees

05/2009 Idiopathic nonspecific interstitial pneumonia: prognostic value of hallwalk distance and changes in physiology., American Thoracic Society International Conference, San Diego, CA (Co-Author)

Details: International presentation, 100 attendees

RESEARCH GRANTS:

Federal

Project #:

Funding Agency: NHLBI, NIH

Title: Study of Clinical Efficacy of Antimicrobial Therapy Strategy Using Pragmatic Design in Idiopathic Pulmonary Fibrosis (CleanUP IPF) Trial within the Pulmonary Trials Cooperative (PTC)

Status: Active

Period: 01/2018 - 01/2020

Role: Contributor

% Effort:

Total Costs:

Grant Detail: At the time of study enrollment completion in June 2019, we were the 6th highest enrolling site amongst 36 sites around the U.S.

Project #:**Funding Agency:** Claude D. Pepper San Antonio Older Americans Independence Center**Title:** Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis**Status:** Complete**Period:** 07/2017 - 11/2019**Role:** Principal Investigator**% Effort:****Total Costs:** \$60,000.00

Grant Detail: Converging evidence implicates cellular senescence in the disease process. Selectively ablating senescent cells in vivo using dasatinib and quercetin (DQ) alleviates symptoms of IPF and frailty in mouse models. In collaboration with Dr. Kirkland's group at Mayo Clinic-Rochester, Drs. Justice and Kritchevsky at Wake Forest University, and Dr. Musi's team at UT Health San Antonio, we conducted a the first-in-human, two-center, open-label pilot study of intermittent dasatinib and quercetin in patients with IPF to evaluate the feasibility of the approach, preliminary estimates of safety, and future trial instruments such as biochemical assays. Of the 14 participants enrolled in the open label pilot study, 12 were recruited from UT Health San Antonio and all completed the study. This first-in-human open-label pilot supported study feasibility and provided initial evidence that senolytics may alleviate physical dysfunction in IPF, warranting evaluation of DQ in larger randomized controlled trials for senescence-related diseases. (ClinicalTrials.gov identifier: NCT02874989). In the fall of 2019, we completed the first-in-human, phase 1b, randomized controlled study of dasatinib and quercetin in IPF (pending analysis). Of the 12 participants enrolled in the randomized controlled study, all 12 were recruited from UT Health San Antonio and completed the study.

Project #:**Funding Agency:****Title:** The MENDS II Study: Maximizing the Efficacy of sedation and reducing neurological dysfunction and mortality in septic patients with acute respiratory failure.**Status:** Complete**Period:** 07/2012 - 06/2017**Role:** Co-Investigator**% Effort:****Total Costs:**

Grant Detail: This multicenter, randomized, controlled trial will be evaluating the efficacy and safety of sedation as well as reducing neurological dysfunction and mortality in septic patients with acute respiratory failure.

Project #: 10-04 CSP 574**Funding Agency:** VA Cooperative Trial # 10-04 CSP 574**Title:** ESCAPE Trial – Extended Steroid (in) CAP(e): A randomized, Placebo Controlled, Double-Blind Trial to Evaluate the Safety and Efficacy of Methylprednisolone in Hospitalized Veterans with Severe Community-Acquired Pneumonia.**Status:** Complete**Period:** 06/2011 - 06/2016**Role:** Co-Investigator**% Effort:****Total Costs:** \$20,000,000.00

Grant Detail: This very important VA Cooperative Trial is a large, multicenter, randomized, placebo-controlled, double-blinded study to evaluate the safety and efficacy of methylprednisolone in severe community acquired pneumonia (CAP). Recently published observational studies, small randomized controlled studies, and meta-analyses suggest a benefit for the use of corticosteroids in severe CAP. If this study does demonstrate clinical and statistical significance in the improvement of severe CAP outcomes, this would be a landmark, practice-changing trial.

Private

Project #:

Funding Agency:

Title: A Phase 3, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibros

Status: Active

Period: 11/2019 - Present

Role: Co-Investigator

% Effort:

Total Costs:

Grant Detail:

Project #:

Funding Agency:

Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

Status: Active

Period: 08/2019 - Present

Role: Co-Investigator

% Effort:

Total Costs:

Grant Detail: In just 4 months after being activated for this study, we were already tied as the 2nd highest enrolling site. As of March 2020, we were the 2nd leading enrolling site amongst 26 sites from around the world.

Project #:

Funding Agency:

Title: An open-label extension trial of the long term safety of nintedanib in patients with Progressive Fibrosing Interstitial

Status: Active

Period: 03/2019 - Present

Role: Co-Investigator

% Effort:

Total Costs:

Grant Detail:

Project #:

Funding Agency: Boehringer-Ingelheim

Title: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Status: Complete

Period: 11/2017 - 11/2019

Role: Contributor

% Effort:

Total Costs:

Grant Detail: We were the 2nd highest enrolling site in the U.S.

Project #:

Funding Agency: Pulmonary Fibrosis Foundation

Title: Pulmonary Fibrosis Foundation Registry

Status: Active

Period: 07/2016 - Present

Role: Co-Investigator

% Effort:

Total Costs:

Grant Detail: At the time that the Registry was closed to further enrollment, we were the 8th highest enrolling center out of 42 PFF Care Centers in the U.S.

Project #: 159563

Funding Agency: Pulmonary Fibrosis Foundation

Title: Pulmonary Fibrosis Foundation Care Center

Status: Active

Period: 01/2016 - Present

Role: Principal Investigator

% Effort: 5

Total Costs: \$7,500.00

Grant Detail:

Project #: PIPF-031

Funding Agency: Intermune

Title: A Treatment Protocol to Allow Patients in the US with Idiopathic Pulmonary Fibrosis Access to Pirfenidone

Status: Complete

Period: 08/2014 - 04/2015

Role: Principal Investigator

% Effort:

Total Costs: \$30,729.00

Grant Detail: This expanded access program enabled patients suffering from idiopathic pulmonary fibrosis the opportunity (IPF) to start on open-label pirfenidone during the period that pirfenidone remained unavailable to the general public. In October 2014, the FDA approved pirfenidone as a treatment for IPF. Patients were allowed to continue on open-label pirfenidone until their health insurance covered their prescription at which time they were transitioned off the study onto commercial pirfenidone.

Project #: GB28547

Funding Agency: Roche/Genentech

Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Idiopathic Pulmonary Fibrosis (RIFF study)

Status: Complete

Period: 08/2013 - 08/2017

Role: Principal Investigator

% Effort:

Total Costs: \$287,095.00

Grant Detail: The RIFF study is a multinational, multicenter, phase 2, randomized, controlled study to evaluate the efficacy and safety of lebrikizumab, an anti-IL-13 agent, in patients with idiopathic pulmonary fibrosis (IPF). It has been suggested that IL-13 plays a pivotal role in the pathogenesis of IPF. This study aims to determine the efficacy of lebrikizumab, specifically to slow down disease progression as measured by the forced vital capacity at 52 weeks. Other important secondary objectives will assess progression-free survival, mortality, exacerbations, quality of life, and adverse events.

Project #: PIPF-12

Funding Agency: Intermune

Title: An Open-Label Extension Study of Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) (ReCAP study)

Status: Complete

Period: 11/2012 - 04/2015

Role: Principal Investigator

% Effort:

Total Costs: \$69,875.20

Grant Detail: This study was an open-label extension study following the ASCEND, a phase 3, randomized, controlled trial on pirfenidone in patients with idiopathic pulmonary fibrosis. The aim of this study was to evaluate the long-term safety of pirfenidone in patients with IPF. After the FDA approved pirfenidone for the treatment of IPF in October 2014, subjects were transitioned from the study to commercial drug once approved by their health insurance.

Project #: ASY12295

Funding Agency: Sanofi-Aventis

Title: A Prospective, Longitudinal, Non-Pharmacologic, Case-Controlled Study to Evaluate Longitudinal Disease Behavior and Biomarker Data Over a 52-week Period in Idiopathic Pulmonary Fibrosis Patients

Status: Complete

Period: 08/2012 - 01/2014

Role: Principal Investigator

% Effort:

Total Costs: \$25,478.00

Grant Detail: This prospective observational study was conducted to evaluate the longitudinal disease behavior and biomarker data in patients with idiopathic pulmonary fibrosis (IPF). To date, there is no well-validated, reliable, and readily available biomarker for IPF. Development of a biomarker with these essential characteristics, either alone but more likely in combination with other parameters, would greatly enable clinicians to more accurately diagnosis, prognosticate, assess disease progression, and predict as well as

measure treatment response. Results of this study have not yet been published by the sponsor.

Project #: HZC113782

Funding Agency: GlaxoSmithKline

Title: A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at risk for cardiovascular d

Status: Complete

Period: 06/2012 - 09/2015

Role: Co-Investigator

% Effort:

Total Costs:

Grant Detail:

Project #: SDI-PMX-NA001

Funding Agency: Spectral Diagnostic Inc

Title: EUPHRATES TRIAL Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock

Status: Complete

Period: 06/2012 - 09/2015

Role: Co-Investigator

% Effort:

Total Costs:

Grant Detail: The EUPHRATES TRIAL is a multicenter, randomized, controlled trial evaluating the use of polymyxin B hemoperfusion in adults treated for endotoxemia and septic shock.

Project #: PIPF-016

Funding Agency: Intermune

Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (The ASCEND Trial)

Status: Complete

Period: 01/2012 - 05/2014

Role: Principal Investigator

% Effort:

Total Costs: \$189,125.00

Grant Detail: The ASCEND trial is considered by many as a landmark clinical study in idiopathic pulmonary fibrosis (IPF). This was a multinational, multicenter, phase 3, randomized, controlled trial evaluating the efficacy and safety of pirfenidone in patients with IPF. This study demonstrated that pirfenidone slowed down disease progression by 50 percent over a 52-week period compared to placebo. Other important secondary endpoints that met statistical significance include improved progression-free survival and less decline in six minute walk distance. In a pre-specified analysis of all-cause mortality in a pooled population of 1247 patients (this trial and two previous similarly designed randomized controlled trials), pirfenidone reduced the risk of death at one year by 48% as compared to placebo. Based on the favorable results of this study published in May 2014, the FDA approved pirfenidone in October 2014 as the 1st ever available therapy for IPF in the United

States.

SERVICE

ADMINISTRATIVE RESPONSIBILITIES:

<u>Dates</u>	<u>Type</u>	<u>Description</u>	<u>Role</u>
06/2013-Present		Pulmonary Function Testing Laboratory at the VA	Co-Director

OTHER SERVICE:

<u>Dates</u>	<u>Type</u>	<u>Description</u>	<u>Role</u>
02/2014-03/2014		InterMune IPF Patient Case Study on Sermo Web Alert	Advisor

12/2013-02/2014		InterMune Interactive Patient Case	Advisor
-----------------	--	------------------------------------	---------

As an expert in the field of IPF, I was invited by InterMune to collaborate on the creation of an interactive patient case that will focus on one patient's journey, bringing the audience through the clinical progression of IPF.

My work with InterMune will help further its commitment to providing educational resources to the IPF-treating community.

My responsibilities would include providing instructive feedback on the content outline and interactive case slides, via teleconferences, WebEx meetings, and e-mail communications.

PATIENT CARE:

<u>Dates</u>	<u>Type</u>	<u>Description</u>	<u>Role</u>
05/2020-Present	Inpatient	VA COVID-19 High-intensity Attending	Attending Physician

From May 16-29, I was the attending physician for the VA COVID-19 High-intensity unit at the Audie L. Murphy VA Hospital, South Texas Health Care System. Along with one pulmonary & critical care fellow and wonderful team of intensive care unit nurses and respiratory therapists, we managed up to three patients with COVID-19 pneumonia and acute hypoxemia respiratory failure.

11/2010-Present	Inpatient	Weekend Transplant Rounds at University Hospital	Attending Physician
-----------------	-----------	--	---------------------

I provide faculty coverage of the lung transplant patients during select weekends.

SERVICE TO GOVERNMENT:

<u>Dates</u>	<u>Type</u>	<u>Description</u>	<u>Role</u>
04/2020-Present	Federal Government	Post-COVID-19 Pulmonary Convalescent Program	Director

There is great concern but much uncertainty regarding possible pulmonary sequelae, especially pulmonary fibrosis, amongst post-COVID-19 survivors. In April 2020, given my ILD expertise, I was asked to design the pulmonary aspects of the multidisciplinary VA COVID-19 Convalescent Program. I was invited to design, coordinate, and lead our VA's post-COVID-19 pulmonary convalescent program, the only one of its kind in South Texas. My goal include learning about the prevalence, characteristics, risk factors, and severity of pulmonary sequelae, particularly pulmonary fibrosis, in survivors of COVID-19 infection with pneumonia in hopes of developing safe and effective treatment strategies to improve patient outcomes.

04/2020-Present	Federal Government	COVID-19 Telehealth Critical Care Consultant for VA	Consultant
-----------------	-----------------------	--	------------

I volunteered to serve as regional virtual critical care consultant for the VA COVID-19 Telehealth Critical Care Consultation Community (C5) program in support of ICUs in COVID hotspots across the VA enterprise . Each VISN assigned one physician capable of providing critical care consultation to regular duties as a national critical care tele-consultant.

04/2020-Present	Federal Government	NIH/NIA Think Tank	Consultant
-----------------	-----------------------	--------------------	------------

I was invited to attend (1 of 15) and present at a NIH/NIA Think Tank for a Common Fund in the use of senolytics in April 2020. Attendees: 20.

08/2019-08/2019	Federal Government	NIH/NIA Workshop on Senolytics	Consultant
-----------------	-----------------------	--------------------------------	------------

In August 2019, I was invited, attended (1 of 25), and presented at a National Institutes of Health (NIH)/National Institute of Aging (NIA) workshop on senolytics. This two-day workshop was entitled: "Repurposing drugs or dietary supplements for their senolytic or senomorphic effects: Considerations for clinical trials." Attendees from around the world included academics, representatives of drug and biotechnology companies, and FDA staff. A report of the workshop will be prepared for publication, which will describe options for addressing issues identified during the discussions.

06/2013-Present	Federal Government	Co-director of the VA Pulmonary Function Testing Laboratory	Co-Director
-----------------	-----------------------	--	-------------

SERVICE TO THE INSTITUTION:

<u>Dates</u>	<u>Type</u>	<u>Description</u>	<u>Role</u>
01/2020-Present	University	Transbronchial lung cryobiopsy protocol at UTHSA/UHS	Co-Leader

In early 2020, I was invited to work with Dr. Philip Ong, our division's interventional

pulmonologist, on a new standardized protocol for the performance of lung cryobiopsies for patients with ILD at UTHSA and University Hospital. This will enable a more accurate and less invasive diagnosis than surgical lung biopsy.

05/2019-Present Hospital University Hospital Community Clinic Director
Outreach Program

In 2019, I was invited to work closely with the University Hospital Lung Transplant team to develop and participate in a community outreach program in Laredo, Corpus Christi, and possibly Austin. This would entail a hybrid of both in-clinic and telehealth consultations for patients with interstitial lung disease. In addition, these endeavors would help foster greater collaboration with local healthcare providers, especially community pulmonologists.

02/2018-02/2020 University UT Health Physicians' Medicine Medical
Subspecialties Clinics Director

In late 2017, I was invited by Dr. Glenn Gross, Vice Chair of Clinical Affairs, and Dr. Reeves, Chair of the Department of Medicine to serve as Medical Director of the UT Health Physicians' (UTHP) Medicine Specialties. During my tenure, I worked closely with Dr. Leverage, UTHP Chief Medical Officer as well as Drs. Reeves and Gross. I spearheaded implementation of a secure cloud-based system called LifeImage, which allows for the seamless uploading of outside radiologic images for review and comparison to new imaging. I encouraged integration of mobile health solutions into the workflow for medicine specialty providers. I also helped streamline provider's templates to maximize clinic efficiency, improve patient access to our clinics, and still maintain amongst the highest patient satisfaction scores of any department.

08/2017-Present University Development of standardized HRCT Developer
imaging protocols for ILD

In collaboration with Dr. C.S. Restrepo, chief of cardiothoracic radiology, we developed standardized imaging protocols (CTD-ILD) for patients at the initial and follow-up visits. These protocols were in accordance with Fleischner Society White Paper, ATS/ERS/JRS/ALAT Clinical Practice Guidelines, and PFF radiology working group recommendations..

05/2017-Present University Vice Chair of UT Health SA IRB-1 Vice Chair

In 2017, I was invited to serve as Vice Chair of the Institutional Review Board-1. I assist with leading and coordinating reviews of clinical research protocols at UTHSA and affiliated institutions. This has further honed my skills as a clinical researcher, particularly with regards to designing study protocols and ensuring patient safety.

11/2015-Present University Center Director, UT Medicine / Medical
UTHSCSA Pulmonary Fibrosis Director
Foundation Care Center

As Founding Director of the University of Texas Health San Antonio (UTHSA) Center for ILD in 2012, my primary goal was to build a regional referral center with a

multidisciplinary approach to diagnosing and managing treatment for ILD patients. Within 4 years, our Center for ILD was recognized by the Pulmonary Fibrosis Foundation (PFF), the world's largest ILD patient advocacy group, as a PFF Care Center, or ILD Center of Excellence in late 2015, at the time one of 45 centers. Currently, we are one of 68 PFF Care Centers in the United States, 5 in the state of Texas, and the only one in South Texas. This tremendous career accomplishment would not have been possible without the unwavering support and mentorship at UTHSA from Drs. Jay Peters, Antonio Anzueto, and Stephanie Levine as well as externally from Drs. Flaherty, Martinez, Ganesh Raghu, and Greg Cosgrove. We have solidified our national recognition as an ILD Center of Excellence as we continue to attract patients nationally and globally.

12/2014-Present		ILD/IPF Multidisciplinary Conference	Medical Director
-----------------	--	---	---------------------

I created, organize, and coordinate this multispecialty conference comprised of pulmonologists, rheumatologists, radiologists, and pathologists to discuss challenging ILD and IPF cases, both inpatient and outpatient. These conferences are open to both academic and community physicians. It is held twice a month and serves as an invaluable educational session for medical students, Medicine residents, and Pulmonary fellows. Today, our Center for ILD continues to have the only South Texas multidisciplinary ILD conference held every two weeks to assist with accurate diagnosis and comprehensive management plans.

09/2014-Present	School	Longitudinal Preceptorship -- UTHSCSA School of Medicine	Mentor
-----------------	--------	---	--------

Michael Cottin -- MS-1

In hopes of creating a more meaningful clinical experience for students, we have created a longitudinal preceptorship program that pairs students with an assigned faculty member throughout the first two years of medical school. Already present in a large number of training institutions across the US, these types of longitudinal preceptorships allow meaningful clinical interactions for students by affording them the chance to shadow experienced physicians. A major goal of this program will be to have students witness the multitude of skills physicians must possess to communicate effectively with different patient personalities, manage dying patients, delegate and interact with support staff, and manage time efficiently.

To promote manageable faculty to student ratios, we would like to invite each of you, as clinical faculty members, to participate as a preceptor in this inaugural program. Briefly, each preceptor will be asked to allow at least one student to visit them in the clinic or hospital for a half day session approximately six times a year. Initially, students will only shadow their preceptor, but as preceptors build confidence in their students, we expect that students will be allowed to perform problem specific portions of the history and physical on select patients. The full expectations of both preceptors and students are outlined in the attached document.

09/2014-Present	School	Longitudinal Preceptorship -- UTHSCSA School of Medicine	Mentor
-----------------	--------	---	--------

Aimee Robinson -- MS-1

01/2014-Present		Founding director of the UT Health SA ILD Program	Director
-----------------	--	---	----------

As Founding Director of the University of Texas Health San Antonio (UTHSA) Center for ILD in 2012, my primary goal was to build a regional referral center with a multidisciplinary approach to diagnosing and managing treatment for ILD patients. Within 4 years, our Center for ILD was recognized by the Pulmonary Fibrosis Foundation (PFF), the world's largest ILD patient advocacy group, as a PFF Care Center, or ILD Center of Excellence in late 2015. Currently, we are one of 68 PFF Care Centers in the United States, 5 in the state of Texas, and still the only one in South Texas. Today, our Center for ILD continues to have the only South Texas multidisciplinary ILD conference held every two weeks to assist with accurate diagnosis and comprehensive management plans. Not only do I believe that we have accomplished our regional goal, but we have solidified our national recognition as an ILD Center of Excellence as we continue to attract patients nationally and globally. All in all, I aspire to continued delivery of high-quality service-related patient care and further growth of our ILD center by ongoing collaboration with community physicians and other ILD Centers of Excellence.

12/2013-12/2013	Department	Physician Advisory Board Meeting	Advisory Committee Member
-----------------	------------	----------------------------------	---------------------------

Invited to participate in a Advisory Board meeting sponsored by Intermune regarding the future role of pirfenidone

11/2013-Present	University	UTHSCSA IRB	Board Member
-----------------	------------	-------------	--------------

VA Representative Board Member on the UTHSCSA Institutional Review Board

08/2013-07/2014	University	Longitudinal Preceptorship -- UTHSCSA School of Medicine	Mentor
-----------------	------------	--	--------

Dawn Zhao -- MS1 to MS2

08/2013-07/2014	University	Longitudinal Preceptorship -- UTHSCSA School of Medicine	Mentor
-----------------	------------	--	--------

Alex Jepsen -- MS1 to MS2

See more detail about the longitudinal preceptorship above.

06/2013-Present	University	STVHCS, ALM Division, Pulmonary Function Laboratory	Co-Director
-----------------	------------	---	-------------

Co-Director

10/2012-Present	University	Editorial Board for the SW Respiratory & Critical Care Chronicles electronic journal	Editorial Board Member
-----------------	------------	--	------------------------

I currently serve on the Editorial Board for the Southwest Respiratory and Critical Care Chronicles electronic journal.

09/2012-12/2012 University Critical Care Clinical Nurse Specialist Mentor

Mentored Angela Ong for a semester during her Critical Care Clinical Nurse Specialist ICU rotation in the UTHSCSA School of Nursing.

08/2012-07/2013 University Longitudinal Preceptorship -- UTHSCSA School of Medicine Mentor

Dev Arwikar -- MS1 to MS2

See more detail about the longitudinal preceptorship above.

09/2011-12/2011 University Critical Care Clinical Nurse Specialist Mentor

Mentored Heather Dysert for a semester during her Critical Care Clinical Nurse Specialist ICU rotation in the UTHSCSA School of Nursing.

06/2011-Present Department ILD/IPF Clinic at UT Medicine MARC Medical Director

As the only dedicated interstitial lung disease (ILD) or idiopathic pulmonary fibrosis (IPF) clinic in the city of San Antonio and entire South Texas region, I currently see patients on two half-days per week. I am referred about 4-6 new consultations from the community per week (16-20 per month) and see about 12-16 follow-up patients per week (40-56 per month). I currently serve as the primary or collaborating pulmonologist for approximately 400 patients. I have a patient rating of 4.8 out of 5.0 (n=159 ratings). Select patient comments include: "Dr. Nambiar is an outstanding doctor. I wish all doctors had his qualities: listening, asking pertinent questions, being engaged and interested, explaining the course of action, and just plain nice!," "Dr Nambiar may be the most understanding and helpful physician I've ever been involved with," "I am overwhelmed with the care and operation of this provider and clinic. Literally the best I have ever had! Thank you for all you do to help your patients," "Dr. Nambiar is providing a second opinion for a pulmonary condition. He is courteous and professional. He is also very personable. My background was provided and he listened. He was very thorough in his examination and questioning. I left my appointment very impressed and confident that I received superior medical care. Thank you!," "Again Dr Nambiar is an asset to your organization," "Dr. Nambiar is a highly respected expert in his field and I feel fortunate to have access to his expertise. The clinic staff have always been pleasant and thoroughly professional," "Dr. Nambiar was phenomenal by every measure, as was his staff of nurses/specialists/technicians."

12/2010-Present Hospital Pulmonary Consultation Service Attending Physician

University Hospital and VA Hospital, simultaneously. 4-16 weeks per year, 40+ hours per week. For more details, especially teaching aspects and trainee comments, please see under

"Teaching Activities."

11/2010-Present	Hospital	Medical Intensive Care Unit: University Hospital and the South Texas Veterans Health Care System (VA Hospital)	Attending Physician
-----------------	----------	---	------------------------

8-16 weeks per year, 50+ hours per week. For more details, especially teaching aspects and trainee comments, please see under "Teaching Activities."

11/2010-Present	Hospital	University Health System - Downtown, Medicine Thoracic Consultant Clinic	Attending Physician
-----------------	----------	--	------------------------

1/2 day, 4-16 weeks per year

10/2010-Present	University	Clinical research trialist	Principal Investigator
-----------------	------------	----------------------------	---------------------------

As a result of long-standing treatment nihilism, decade's-long use of harmful medications for certain ILDs, only two currently approved therapies for idiopathic pulmonary fibrosis, and significant unmet need for better, safer treatments, I recognized early in my academic career that it was essential to integrate clinical research into my care for patients with ILD. Following completion of my Master's in Clinical Investigation at UTHSA in 2016, I have been actively involved in numerous investigator-initiated and industry-sponsored clinical trials, as outlined in the research section of my Curriculum Vitae.

SERVICE TO THE PROFESSION:

<u>Dates</u>	<u>Type</u>	<u>Description</u>	<u>Role</u>
02/2020-Present	International	Editorial Board Member for Touch Respiratory	Editorial Board Member

touchRESPIRATORY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.

10/2018-10/2018	International	Intersitial Lung Disease: Update on Patient-Centered Management	Co-Chair
-----------------	---------------	--	----------

I served as co-chair for the design, coordination, and implementation of this problem based learning exercise at the 2018 CHEST International Conference. Attendees included community pulmonologists and fellows in training learned about various ILD diagnostic and therapeutic approaches through real-world cases followed by discussion by expert faculty. Attendees: 75.

09/2018-11/2019	International	Pulmonary Fibrosis Foundation Summit 2019 Co-Chair	Co-Chair
-----------------	---------------	---	----------

In 2018, I was invited by Dr. Cosgrove, PFF Chief Medical Office, to co-chair the biennial PFF Summit to be held in San Antonio, the largest pulmonary fibrosis conference in the

world that brings the entire community of clinicians, researchers, patients, and their families together. In November 2019, it was an honor and privilege to serve as PFF Summit Co-chair along with Dr. Joseph Lasky and Dot Delarosa for the largest international Summit to-date with nearly 1,000 attendees from around the world.

10/2017-10/2017	International	CHEST 2017 Interdisciplinary ILD Session	Co-Chair
-----------------	---------------	--	----------

I served as co-chair for the design, coordination, and implementation of this problem based learning exercise at the 2017 CHEST International Conference. Attendees included community pulmonologists and fellows in training learned about various ILD diagnostic and therapeutic approaches through real-world cases followed by discussion by expert faculty. Attendees: 65.

12/2012-Present	International	Reviewer for multiple medical journals	Reviewer
-----------------	---------------	--	----------

I have served as reviewer for multiple manuscripts submitted to multiple medical journals (listed below in alphabetical order):

- 1. American Academy of Family Physicians*
- 2. American Journal of Managed Care*
- 3. American Journal of Respiratory and Critical Care Medicine*
- 4. Annals of American Thoracic Society*
- 5. British Medical Journal Open*
- 6. CHEST*
- 7. European Respiratory Journal*
- 8. Lung*
- 9. Respiratory Medicine*
- 10. Respirology*
- 11. Seminars in Arthritis & Rheumatology*
- 12. Southwest Respiratory and Critical Care Chronicles*
- 13. Touch Respiratory*

03/2011-Present	International	Fellow of the American College of Chest Physicians	Fellow
-----------------	---------------	--	--------

Elected to Fellowship in the American College of Chest Physicians (ACCP), one of the largest and most important pulmonary and critical care professional organizations in the world.

SERVICE TO THE PUBLIC:

<u>Dates</u>	<u>Type</u>	<u>Description</u>	<u>Role</u>
05/2020-Present	Community	Virtual San Antonio Pulmonary Fibrosis Support Group	Medical Director

Due to the COVID-19 pandemic and importance to stay home, especially for high-risk patients with pulmonary fibrosis, we have teamed up with the Pulmonary Fibrosis Foundation to have our monthly support group meetings virtually through ZOOM. Twenty-

Later in 2019, I was invited as an ILD expert consultant in an industry-funded initiative to improve ILD diagnosis and management in the U.S. Veterans Affairs (VA) Hospitals. Boehringer-Ingelheim's goal is to improve awareness and access to the highest-quality diagnostic and therapeutic options for veterans with ILD.

05/2019-Present	Patient Care Community	First-in-Texas to utilize Envisia Genomic Classifier	Physician
-----------------	---------------------------	---	-----------

To help improve diagnostic accuracy, in 2019, I performed the first-in-Texas Envisia Genomic Classifier test using transbronchial lung biopsies at University Hospital. This novel genomic diagnostic test helps to accurately and less invasively identify a histopathologic pattern of usual interstitial pneumonia, the pattern of fibrotic ILD associated with IPF with no other cause or association. This achievement was highlighted in the San Antonio MD News on 5/31/19: <https://sanantonio.mdnews.com/test-deadly-lung-disease-used-first-time-texas>. Continued implementation of this novel diagnostic test has helped correctly diagnose many patients since with IPF without subjecting them to a surgical lung biopsy.

02/2018-02/2018	Community	4th Free ILD Clinic	Medical Director
-----------------	-----------	---------------------	---------------------

Similar to our previous free clinics, we provided free, same-day lung function testing (breathing tests, or PFTs, and six-minute walk testing courtesy of Dr. Mary Hart and the UTHSCSA Respiratory Care students using equipment donated by ndd Medical Technologies) and a private, personalized, and comprehensive ILD consultation with me.

Following these stations, we also had a medico-legal station coordinated by my wife, Devi, and her colleagues who volunteered their time and legal expertise with regards to very important issues such as establishing living wills, advance directives, etc.

01/2016-01/2016	Patient Care Community	3rd Free ILD Clinic	Medical Director
-----------------	---------------------------	---------------------	---------------------

Similar to our previous free clinics, we will be providing free, same-day lung function testing (breathing tests, or PFTs, and six-minute walk testing courtesy of Dr. Mary Hart and the UTHSCSA Respiratory Care students using equipment donated by ndd Medical Technologies) and a private, personalized, and comprehensive ILD consultation with me.

Following these stations, we will have a new medico-legal station coordinated by my wife, Devi, and her colleagues who will be volunteering their time and legal expertise with regards to very important issues such as establishing living wills, advance directives, etc.

02/2015-Present	Patient Care Community	2nd Annual Free ILD/IPF Clinic	Medical Director
-----------------	---------------------------	--------------------------------	---------------------

With the help of Dot Delarosa (founder of the support group) and the Pulmonary Fibrosis Foundation Leanne Storch Support Group Fund, we created, designed, organized, and coordinated our 2nd free clinic. With the assistance of Mary Hart and the UTHSCSA Respiratory Care students, we also performed pulmonary function and exercise testing using donated equipment. Our free clinic was also highlighted in the Pulmonary Fibrosis

Foundation Spring 2015 Breathe Bulletin.

05/2014-Present Patient Care 1st Annual Free ILD/IPF Clinic Medical
Community Director

With the help of Dot Delarosa (founder of the support group), we created, designed, organized, and coordinated this free clinic for patients and families with suspected or confirmed ILD or IPF to obtain an expert second opinion.

04/2012-Present Health Physicians Advisory Board member Advisory Board
Education of the Pulmonary Fibrosis Member
Association of Texas

I was invited to serve on the Physicians Advisory Board of the Pulmonary Fibrosis Association of Texas. I have provided input on creation, development, and coordination of various endeavors to improve education about pulmonary fibrosis amongst patients and their caregivers.

01/2012-Present Patient Care Pulmonary Fibrosis Support Group of Medical
Community San Antonio Director

I serve as the medical director of the group which meets monthly to provide high-quality educational, emotional, and financial support to IPF patients in San Antonio. I volunteer a weekend morning to give monthly presentations on various IPF topics. Approximately 40 ILD patients have self-referred themselves to my UTHP MARC ILD Clinic. In May 2020, due to COVID-19 pandemic social gathering restrictions and for the safety of our high-risk vulnerable ILD patients, we held our first virtual support group meeting attended by 20 patients and their caregivers.

02/2009-02/2009 Medical Volunteer-Peruvian Amazon Volunteer
w/Amazon Promise

Medical Volunteer/Aguarunas Indian villages of the Peruvian Amazon with Amazon Promise, a non-profit organization (www.amazonpromise.org) providing volunteer medical care to villages in one of the most isolated jungle regions in the world.

07/2000-07/2000 Medical Volunteer-Child Family Volunteer
Health-India

Medical Volunteer/Rural-Urban Himalayan Rotation in India with Child Family Health International. Traveled throughout the foothills of the Indian Himalayas and New Delhi, India learning about both the practice of Western Medicine and Ayurveda, an ancient form of traditional medicine dating back thousands of years.

PROFESSIONAL AFFILIATIONS:

Dates

Organization

11/2011-Present Pulmonary Fibrosis Foundation

Additional Details: The Pulmonary Fibrosis Foundation (PFF) is the largest non-profit patient advocacy organization in the world for patients and caregivers suffering from

pulmonary fibrosis. By actively engaging the PF community, the Pulmonary Fibrosis Foundation has developed essential programs available to those living and working with pulmonary fibrosis. The Pulmonary Fibrosis Foundation is focused on our mission to act as the trusted resource for all who are affected by this disease. Our community programs include: PFF Care Center Network PFF Patient Registry PFF Patient Communication Center PFF Ambassador Program An international network of support groups The PFF Summit Comprehensive disease education materials

08/2009-Present European Respiratory Society
Additional Details: a) Active member since 2009 b) Attended ERS 2009 in Vienna, Austria

01/2008-Present American College of Chest Physicians
Additional Details: a) Active member since 2007 b) Nominate and elected a Fellow of the Chest College of Physicians (FCCP) in 2010

01/2006-Present American Thoracic Society
Additional Details: a) Active member since 2007 b) Attended ATS 2007 thru 2015 c) I have given multiple presentations (posters, thematic discussions) d) Facilitator, ILD/IPF poster session at ATS 2014 in San Diego e) I am currently serving on the Clinical Problems assembly program committee (2014 to present). This committee is actively involved in programming the clinical and research sessions of the annual American Thoracic Society International Conference.

COMMITTEES (UTHSCSA Standing Committees):

UNIVERSITY

<u>Dates</u>	<u>Committee</u>	<u>Role</u>
01/2017-Present	Institutional Review Board	Vice-Chair
	<i>In January 2017, I was nominated to serve as deputy chair of IRB-1. I am also one of three VA representatives on each of the three boards. Meetings are held once every 6 weeks. For the 3 hour meeting, I spend approximately 5 hours reviewing new research protocols, amendments, and/or progress notes for approved protocols. This is in preparation to formally present my review to the IRB.</i>	
11/2013-Present	Institutional Review Board	Board Member

COMMITTEES (OTHER):

HOSPITAL

<u>Dates</u>	<u>Committee</u>	<u>Role</u>
05/2011-Present	Mock Code Planning Committee, Audie L. Murphy Memorial VA Hospital, Medicine	Member
	<i>Plan, organize, and facilitate simulated (mock) cardiac arrests (code blue) for the entire ALM VA Hospital.</i>	

OTHER

<u>Dates</u>	<u>Committee</u>	<u>Role</u>
07/2019-Present	CHEST Foundation Erin Popovich Endowment Task Force	Consultant
<i>I was invited to be on a 5-member programming panel of ILD experts for the CHEST Foundation Erin Popovich Endowment Task Force. Thus far, we have developed multiple ILD educational materials for patients and families as well as their physician providers.</i>		
11/2017-Present	Pulmonary Fibrosis Foundation Rural Health Working Group	Co-Chair
<i>Actively working to develop programs utilizing the resources of the Pulmonary Fibrosis Foundation that are aimed at improving the care of ILD patients in rural community areas.</i>		
01/2014-Present	American Thoracic Society (ATS) Clinical Problems Assembly Program Committee	Member
<i>As a member of the Program Committee of the Clinical Problems Assembly, I am actively involved in creating, organizing, and coordinating the various clinical sessions at the annual American Thoracic Society (ATS) International Conference.</i>		